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ABSTRACT
Nek2 (NIMA-related kinase 2) is a cell cycle-dependent serine/threonine 
protein kinase that regulates centrosome separation at the onset of mitosis. 
Overexpression of Nek2 is common in human cancers and suppression can restrict 
tumor cell growth and promote apoptosis. Nek2 inhibition with small molecules, 
therefore, offers the prospect of a new therapy for cancer. To achieve this goal, a 
better understanding of the requirements for selective-inhibition of Nek2 is required. 
6-Alkoxypurines were identified as ATP-competitive inhibitors of Nek2 and CDK2. 
Comparison with CDK2-inhibitor structures indicated that judicious modification of 
the 6-alkoxy and 2-arylamino substituents could achieve discrimination between 
Nek2 and CDK2. In this study, a library of 6-cyclohexylmethoxy-2-arylaminopurines 
bearing carboxamide, sulfonamide and urea substituents on the 2-arylamino ring 
was synthesized. Few of these compounds were selective for Nek2 over CDK2, with 
the best result being obtained for 3-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)-
N,N-dimethylbenzamide (CDK2 IC50 = 7.0 μM; Nek2 IC50 = 0.62 μM) with >10-fold 
selectivity. Deletion of the 6-substituent abrogated activity against both Nek2 and 
CDK2. Nine compounds containing an (E)-dialkylaminovinyl substituent at C-6, all 
showed selectivity for Nek2, e.g. (E)-6-(2-(azepan-1-yl)vinyl)-N-phenyl-9H-purin-
2-amine (CDK2 IC50 = 2.70 μM; Nek2 IC50 = 0.27 μM). Structural biology of selected 
compounds enabled a partial rationalization of the observed structure activity 
relationships and mechanism of Nek2 activation. This showed that carboxamide 11 
is the first reported inhibitor of Nek2 in the DFG-in conformation.
INTRODUCTION
Abnormalities in centrosome number and function 
are common in many cancers, indicating that loss of 
centrosome cycle regulation may be a major factor in 
tumor progression [1]. Nek2 (NIMA-related kinase 2) is 
a human cell cycle-dependent serine/threonine protein 
kinase that localizes to the centrosome [2]. Nek2 is 
related to the fungal protein NIMA (never in mitosis gene 
A), an essential mediator of mitotic entry in Aspergillus 
nidulans. Like NIMA the activity of Nek2 peaks prior 
to mitotic entry, although in contrast to NIMA, Nek2 is 
not essential for mitotic entry in human cells. However, 
Nek2 does play a key role in ensuring timely assembly 
of the mitotic spindle, a scaffold that is vital for accurate 
segregation of sister chromatids during mitosis [3]. Nek2 
interacts with centrosomal proteins that assemble into 
a filamentous linker that holds centrosomes in close 
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proximity throughout interphase. Phosphorylation of these 
proteins by Nek2 in late G2 promotes linker disassembly 
and loss of centrosome cohesion; this in turn allows 
the timely separation of centrosomes in prophase [4]. 
In addition, Nek2 can promote cell cycle progression 
through phosphorylation of motor proteins that lead to 
disassembly of primary cilia [5]. Overexpression of Nek2 
results in premature centrosome separation, which is a 
cause of chromosome segregation errors, aneuploidy and 
chromosomal instability, common genetic abnormalities 
observed in tumor cells. Upregulation of Nek2 expression 
has been observed in many human tumors, including 
ovarian [6], colorectal [7], prostatic [8], hepatocellular 
carcinoma [9] and breast cancer [10]. Nek2 depletion in 
a number of tumor cell lines causes growth suppression 
and apoptosis, while anti-tumor activity has been reported 
in a range of tumor cell lines following abrogation of 
Nek2 activity by RNAi depletion alone, or combined with 
cisplatin [11–14]. Hence, inhibiting Nek2 with small-
molecule kinase inhibitors has potential as a novel cancer 
therapy.
Increasing efforts are now being applied to the 
development of Nek2 inhibitors with several small 
molecule inhibitors disclosed (Table 1). Examples include 
the aminopyrazine ATP-competitive inhibitor 1 (Nek2IC50 
= 0.23 μM) [15] and a benzimidazole-based series with > 
200-fold selectivity for Nek2 over Plk1 (e.g. 2:Nek2 IC50 
= 0.36 μM) [16]. To address the modest ligand efficiency 
(LE) of 2, a hybrid class of compounds was generated by 
combining the core aminopyrazine moiety of the initial 
series with side-chains from the benzimidazole series. 
Optimisation of this new class of inhibitors improved 
potency, LE and kinase selectivity against a panel of cell 
cycle kinases, and culminated in the identification of 3 
(Nek2 IC50 = 0.022 μM) [17]. A series of ATP-competitive 
reversible Nek2 inhibitors was also identified via high-
throughput screening. These viridin/wortmannin-like 
compounds exhibited only modest Nek2-inhibitory 
activity (e.g. 4:Nek2 IC50 = 1.9 μM), albeit with selectivity 
over other Nek family members. In addition, some activity 
was observed in cellular growth inhibition and centrosome 
separation assays [18]. More recently, an irreversible 
inhibitor (5) of Nek2 was identified via structure-guided 
design [19]. Interestingly, compound 5 was shown to 
react with the Cys22 residue of Nek2 and achieved sub-
micromolar activity (Nek2 IC50 = 0.77 μM).
In the present study, a medium-throughput screen 
revealed that purines bearing 6-alkoxy substituents were 
ATP-competitive inhibitors of both Nek2 and CDK2 (e.g. 
6: CDK2 IC50 = 0.005 μM; Nek2 IC50 = 12 μM) (Table 
1). Modifications around the purine scaffold were carried 
out to repurpose this class of kinase inhibitor to improve 
the potency against Nek2, whilst reducing activity against 
CDK2. Whilst it is acknowledged that a significant extent 
of structural homology exists between kinome members, 
and dissecting CDK2 inhibiton from Nek2 inhibition 
was expected to present a significant challenge, it was 
considered that structural differences between the two 
proteins could be highlighted using appropriately designed 
probes. From our initial screen, it was evident that in 
particular, purines bearing meta- or para-substituted 
2-arylamino groups that contained a basic functionality 
afforded improved selectivity for Nek2 over CDK2 (e.g. 
7: CDK2 IC50 = 5.6 μM; Nek2 IC50 = 0.89 μM).
This paper describes extensive structure-guided 
design, synthesis and structure-activity relationship 
(SAR) studies conducted with the purine scaffold and 
directed towards the development of potent and selective 
reversible Nek2 inhibitors. These tools have provided 
an initial insight in to some of the key requirements for 
selective inhibition of Nek2 over CDK2 using purine-
based inhibitors.
RESULTS AND DISCUSSION
Structure-guided inhibitor design
As a starting point for understanding the mode of 
binding of arylaminopurines to Nek2, the X-ray crystal 
structure of 8, identified from the initial screening, was 
determined in complex with Nek2 and revealed that the 
compound binds via a hydrogen bonding triplet between 
the purine N9-H, N3 and C2-NH, and the kinase hinge 
region residues Cys-89 and Glu-87 (Figure 1). Alkylation 
or removal of the participating purine nitrogen atoms 
would, therefore, be expected to be detrimental to 
activity towards Nek2 as for CDK2 and offer no basis 
for differentiation. However, the 6-alkoxy substituent 
was considered a candidate for remodeling of prototype 
inhibitors to differentiate between Nek2 and CDK2 
inhibition. The 6-cyclohexylmethyl group occupies a 
lipophilic cavity near the ribose-binding pocket in CDK2 
and is critical for activity [20]. A van der Waals contact 
may be formed between the 2-arylamino group and Gly-
92. No definite interactions were observed between the 
amide functionality of 8 with the binding site, although 
the amide group is close to Asp-93 (Figure 1C), and it was 
considered that this may be exploitable.
A comparison of the purines 6 and 8 in the CDK2 
and Nek2 ATP-binding sites is shown in Figure 2. The 
aromatic ring systems of 8 in Nek2 are co-planar, whereas 
for 6 bound to CDK2 the 2-arylamino ring is rotated ~13° 
relative to the purine core due to sulfonamide interactions 
with Asp-86 (equivalent to Asp-93 of Nek2). Thus, 
interactions between the 3-benzamide moiety and the 
Nek2 binding site do not appear to affect the conformation 
of the purine. As a starting point for these studies, it was 
proposed that selective inhibition of Nek2 over CDK2 
may be achieved through judicious modification of the 
purine 2-arylamino motif or the O6-substituent.
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Number Structure Nek2 inhibitory activity IC50 / µM
Reference
1 0.23 15
2 0.36 16
3 0.022 17
4 1.9 18
5 0.77 19
6 12.0 -
7 0.89 -
Table 1. Examples of reported small molecule Nek2 inhibitors
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Synthesis of purine-based probes for selective 
Nek2 inhibition
Modifications at the 2-Arylamino Position
Investigation at the purine 2-position began with 
the synthesis of simple 2-arylamino purine derivatives 
containing hydrogen-bond donors/acceptors, in which 
the substitution pattern around the aryl ring was varied 
and the linker length between the ring and various 
functionalities was altered. From the initial screening 
data, several structural motifs at this position showed 
Nek2 inhibition, including carboxamides, sulfonamides 
and ureas. These served as the targets for synthesis. Initial 
compounds were prepared by direct nucleophilic aromatic 
substitution of a purine 2-fluoro substituent of 9 with a 
range of anilines (see supporting information for synthesis 
of corresponding anilines where otherwise not shown); a 
second approach allowed diversification of some of these 
simple 2-arylamino-purines.
As one of the original hits from the screen was a 
carboxamide derivative, it was decided to begin this 
study by synthesising analogues of the carboxamide to 
investigate how this may be modified. Carboxamides 
10 and 11 and related thiocarboxamides 12 and 13 were 
prepared by reaction of fluoropurine 9, with either a 
commercially available or a synthesized (see ESI) aniline, 
in 2,2,2-trifluoroethanol (TFE) containing trifluoroacetic 
acid (TFA) [20–22] (Scheme 1). A carboxamide isostere, 
the thiocarboxamide group, was investigated as the 
sulfur atom of a thioamide is a weaker hydrogen bond 
acceptor than the oxygen atom of an amide, but has a 
stronger hydrogen bond donating ability at the NH [23].
The sulfonamide equivalent of carboxamide 11 was 
synthesized via a similar route affording 14.To probe 
Figure 1: X-ray crystal structure of Nek2 in complex with 6-alkoxypurine inhibitor 8. A. View of compound 8 (carbon atoms 
coloured green) in the ATP-binding pocket of Nek2 (carbon atoms coloured beige). H-bonds are shown as dashed lines. A 2mFo-dFc electron 
density map is shown as a blue wire-mesh around the compound. B. View of the ATP-binding pocket of Nek2 shown as a surface. C. Crystal 
structure of carboxamide 8 (green) bound to the T175A Nek2 mutant (carbon atoms are coloured yellow, oxygen coloured red, and nitrogen 
coloured blue). Hydrogen bonds are represented as dotted lines and important residues are highlighted.
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the effect of sidechain homologation of compound 10, 
N-methyl-homocarboxamide 15 was prepared from the 
corresponding precursor, 3-aminophenyl-(N-methyl)-
acetamide (see ESI). Compounds 16-18, comprising 
a urea motif bearing linkers to a terminal basic group, 
were also prepared according to the standard method 
using synthesised anilines (see ESI). Para- and meta-
nitrophenylaminopurines 19 and 20 were prepared in the 
same manner and subsequently converted in to the amino 
compounds (21 and 22) by catalytic hydrogenation. 
Anilines 21 and 22, carboxylic acids 23 and 24 and 
sulfonate ester 26 were prepared principally for further 
elaboration of the 2-arylamino sidechain (Scheme 2).
As indicated, para- and meta-
aminophenylaminopurines 21 and 22 (Scheme 1) were 
treated with acyl chlorides to provide the desired N-acyl 
aniline ‘reversed amide’ derivatives 27-30 without purine 
N-9 protection (Scheme 2). In addition to the desired 
products, the reaction also afforded an unstable acylation 
product at the purine N-9, which was easily removed by 
treatment with TFA. This allowed the investigation of the 
exact preferences for the amide group orientation, as well 
as the substitution position at the 2-arylamino group. To 
investigate whether a second hydrogen bond-donor group 
could form additional favourable interactions over that of 
a simple carboxamide and to quantify this in comparison 
with more complex urea derivatives, the parent urea e.g. 
31 was prepared. Arylureas were synthesised by treatment 
of precursor aniline 22 with isocyanic acid (HN=C=O), 
generated in situ from sodium cyanate and TFA (Scheme 
2) [24]. As previously observed within the reversed amides 
series, an undesired urea product was also formed at the 
purine N-9 and was cleaved by treatment with TFA.
For the synthesis of a focussed set of 
homocarboxamides a convergent multiple-parallel 
approach was undertaken (Scheme 2). Using carboxylic 
acids 25 and 26 a library of amides (32-47) was obtained 
by coupling with aliphatic or aromatic amines [25, 26]. 
To further understand the effect of homologation of the 
hydrogen bond donor-acceptor group, a series of N-2-
arylmethanesulfonamides (48-52) was also synthesized 
from the parent 2,2,2-trifluoroethanesulfonate 26 
(Scheme 2). To complete the SARs, the meta-substituted 
methylsulfonamide 53 was also synthesized by 
deprotection of the p-methoxybenzyl (PMB) group of 52.
Modifications at the O6-Alkyl Position
Deletion and contraction of the 6-cyclohexylmethyl 
substituent
Crystal structures of Nek2 and CDK2 suggested that 
the O6-cyclohexylmethyl group was more important for 
CDK2 inhibition than Nek2, and indicates that varying the 
size and conformation of the purine 6-substituent might enable 
discrimination between Nek2 and CDK2. Furthermore, a 
suitable group at this position could possibly make a favorable 
interaction with Lys-37 (K37), which is near the ribose 
binding pocket of Nek2 (Figure 3B). Although CDK2 also 
has a lysine residue (K33) near the ribose site (Figure 3A), 
its disposition and environment differs and so substituents 
at the purine 6-position could increase Nek2 selectivity by 
exhibiting a selective impact on its Lys-37.
Purines bearing O6-alkyl substituents, ethyl and sec-
butyl (59 and 60, respectively), were prepared from the 
6-chloropurine precursor (54), by 6-position substitution 
with alkoxides, followed by addition of anilines at the 
2-position that had been found to confer Nek2 inhibition 
Figure 2: Structural overlay of 8-T175A-Nek2A complex (green and cyan) and the 6-T160pCDK2-cyclin A (pink and 
yellow). Rotation of the 2-arylamino group with respect to the purine is only observed for 6 in CDK2, but not for 8 in Nek2.
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(Scheme 3). To overcome some purification problems 
encountered during the synthesis of purines with 
dimethylaminopropyl side chains, carboxylic acid 61 was 
synthesized and used without further purification in the 
preparation of 1-(3-aminopropyl)imidazole derivative 62.
To provide a reference point for these studies, 
the 6-substituent was deleted entirely. Thus, the 
6-unsubstituted intermediate 64 was prepared from 
2-fluoro-6-chloropurine (63) [27], by selective 
dehalogenation of the 6-chloro group using catalytic 
transfer hydrogenation [28, 29]. Coupling of 64 with the 
appropriate anilines gave derivatives 65 and 66, with 66 
being converted to amide 67 (Scheme 4).
Replacement of the O6-cyclohexylmethyl 
substituent
Given the differences between the ribose-binding 
domains of Nek2 and CDK2, it was considered that 
potency may be improved and off-target activity reduced, 
if the group at C-6 could be conformationally restricted 
by the introduction of an alkene. This premise was 
explored by synthesis of (E)-6-(2-dialkylaminovinyl)
purines (69-73). 6-Ethynyl- and 6-vinylpurines have been 
reported as substrates for conjugate addition reactions 
with secondary amines affording (E)-enamines or 
ethylamines, respectively [30, 31]. Addition of primary 
amines to a 6-ethynyl group afforded an inseparable 
mixture of (Z)- and (E)-enamines as a consequence of 
imine-enamine tautomerism. Reported conditions for 
this transformation utilized purine N-9 protection and 
typically required lengthy reaction times of 1-3 days at 
room temperature [30]. We found that the addition of 
amines to the 6-ethynylpurine 68 could be accelerated by 
microwave heating (Scheme 5). 6-Ethynylpurine 68 was 
prepared from N-9 THP-protected 2-fluoro-6-chloropurine 
utilizing Sonagashira alkynylation. Following cleavage 
of the N-9 hemiaminal ether by acidic hydrolysis, 
introduction of the 2-arylamino group and silyl group 
deprotection afforded the alkynyl intermediate. In all cases 
Scheme 1: Synthesis of 2-substituted purine derivatives I.a
a  Reagents and conditions: (a) Appropriate aniline, TFA, 2,2,2-trifluoroethanol, 90 °C, 18 h, 17-77%; (b) Pd/C, H2, MeOH, 
RT, 18 h.
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Scheme 2: Synthesis of 2-substituted purine derivatives II.a a Reagents and conditions: (a) i. RCOCl, Et3N, DMAP, THF, RT (or 
70 °C as required), 18 h, 31-81%; ii. TFA, DCM, RT, 18 h, 43 - 100%; (b) i. NaOCN, TFA, DMF, RT, 18 h; ii. TFA, DCM, RT, 18 h; (c) i. 
CDI, DIPEA, DMF, RT, 90 min; ii. RR'NH, RT, 18 h, 20-81%; (d) i. DBU, RR'NH, THF, MW, 160 °C, 15 min; ii. (for compound 53) 52, 
TFA (neat), RT, 6 h, 85%.
Figure 3: Binding of purine 6 to: A. active Thr 160-phosphorylated CDK2-cyclin A complex (T160pCDK2-cyclin A); and B. inactive 
Nek2.
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the subsequent conjugate addition took place smoothly 
in moderate-to-high yield without N-9 protection and a 
series of (E)-enamines (69-73) was obtained (see ESI for 
more examples). The configuration at the newly formed 
double bond was validated by 1H NMR (3J = 15.0 Hz). 
This methodology is applicable for the facile synthesis 
of enamine derivatives from a diverse set of secondary 
amines.
Biological evaluation of synthesized purines
Preliminary data attained following a medium-
throughput screening campaign, identified purines 
bearing 6-alkoxy substituents (e.g. 6; CDK2 IC50 = 0.005 
μM; Nek2 IC50 = 12 μM) as dual inhibitors of Nek2 and 
CDK2. Interestingly, deletion of the sulfonamide moiety 
from 6, resulted in a 200-fold reduction in CDK2 inhibitor 
activity as well as some reduction in Nek2 activity 
(2-aminophenyl-6-(cyclohexylmethoxy)-9H-purine: CDK2 
IC50 = 1 μM; Nek2 IC50 = 22 μM). To gain a further 
understanding of the requirements for selective Nek2 
inhibition, a structure-activity study was undertaken to 
explore the scope for modification of the purine hits at the 
2- and 6-positions.
Modifications at the 2-arylamino position
We have previously reported that hydrogen bond 
donor-acceptor groups, such as sulfonamides at the 
2-arylamino position, form important interactions (e.g. 
with Asp-86) at the ‘specificity surface’ of CDK2 [32].
Scheme 3: Synthesis of O6-alkyl-2-arylaminopurines.a a Reagents and conditions: (a) ROH, Na, reflux, 18 h; (b) HBF4, NaNO2, 
H2O, 0 °C → RT, 24 h; (c) (i) 3-aminophenylacetic acid, TFA, 2,2,2-trifluoroethanol, 90 °C, 24 h, (ii) NaOH, THF/H2O,RT, 18 h; (d) TFA, 
2,2,2-trifluoroethanol, 90 °C, 18 h; (e) (i) CDI, DIPEA, DMF, RT, 90 min, (ii) 1-(3-aminopropyl)imidazole, RT, 18 h.
Scheme 4: Synthesis of 6-unsubstituted 2-arylaminopurines.a a Reagents and conditions: (a) HBF4, NaNO2, 0 °C to RT, 75 min, 
75%; (b) Pd(OH)2, NH4OOCH, MeOH, 65 °C, 1 h, 100%; (c) (i) anilines, TFA, 2,2,2-trifluoroethanol, 90 ºC, 48 h; (ii) for 66: KOH, THF/
H2O, RT, 18 h 34-45%; (d) (i) CDI, DIPEA, DMF, RT, 90 min; (ii) RNH2, RT, 18 h, 40 – 59%.
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To discriminate between the interactions required for 
Nek2 inhibition and CDK2 inhibition, variations of 
the 2-arylamino substitution were studied by synthesis 
of acetamide, carboxamide, sulfonamide and urea 
derivatives. Both 4- and 3-nitro-substituted precursors 
were inactive against Nek2 yet retained modest potency 
against CDK2 (19; CDK2 IC50 = 1.9 μM; Nek2 IC50 = > 
50 μM and 20; CDK2 IC50 = 0.89 μM; Nek2 IC50 = > 50 
μM, respectively). The corresponding aniline improved 
activity against Nek2 in both cases (21; CDK2 IC50 = 0.22 
μM; Nek2 IC50 = 6.3 μM and 22; CDK2 IC50 = 0.7 μM; 
Nek2 IC50 = 5.9 μM, respectively), suggesting that there 
may be a hydrogen-bonding interaction available in the 
Nek2 ATP-binding domain. Activity was not enhanced 
by acylation of the respective aniline compounds, with 
N-acetyl compound 27, showing only weak activity 
against Nek2. Further homologation and branching of 
the acyl group of the 4-substituted derivatives did not 
enhance Nek2 inhibition (e.g. 28), and substantial loss 
of Nek2 inhibitory activity occurred with benzoyl (29) or 
isonicotinoyl (30) groups.
The 3-substituted purine 8 had modest activity 
against CDK2 (IC50 = 0.48 μM) and weak activity against 
Nek2 (IC50 = 19 μM). Addition of a methyl substituent 
at the amide nitrogen (compound 10) reduced potency 
against CDK2 but only marginally increased Nek2. 
Reversing the orientation of the carboxamide group (27; 
CDK2 IC50 = 0.88 μM; Nek2 IC50 = 8.3 μM) increased 
Nek2 inhibition in comparison to 8, without increasing 
activity against CDK2. However, unexpectedly, addition 
of a second methyl group to produce the dimethylamide 
11 afforded a marked increase in Nek2 inhibitory activity 
whilst also greatly reducing CDK2 inhibition, suggesting 
that the amide NH hydrogen bond may not be required 
for Nek2 inhibition. Although tethering the dimethylamino 
group into a ring, as in piperidine derivative 32, further 
reduced CDK2 inhibitory activity, Nek2 inhibition was 
also abolished.
Replacing the carboxamide group by a carboxylate 
(23) increased Nek2 activity (IC50 = 4.3 μM) compared 
to 8, indicating a possible ionic interaction with the 
carboxylate and that one hydrogen bond donor is optimal. 
However, 23 still retained potency against CDK2 (IC50 
= 0.99 μM). The thioamides 12 and 13 were similar in 
potency to their amide equivalents (11 and 8) against 
CDK2, but were less active against Nek2.
Overall, the SARs around the amides, benzamides 
and thioamides at the meta position of the 2-arylamino-
O6-cyclohexylmethylpurines revealed that a hydrogen 
bond donor at the meta position favoured activity against 
CDK2 (e.g. 8, 10, 13, 23), whereas introducing a larger, 
bulkier substituent (32) was unfavourable for activity 
against both CDK2 and Nek2 (Table 2). Furthermore, the 
dimethylcarboxamide 11 was both the most potent Nek2 
inhibitor and the compound with the greatest Nek2/CDK2 
selectivity (> 10-fold) in this series. These observations 
could possibly be rationalised through a putative 
interaction with Asp-93 (Figure 4), and may also be the 
case with primary carboxamide 8 in Figure 1; however, no 
direct evidence for this supposition has yet been attained.
With the homocarboxamide series (Table 2, sub-
structure C), removing the donor NH of the amide group 
by synthesis of di-substituted carboxamides (37 and 38) 
in general retained affinity for CDK2 but not Nek2. 
This observation was clearly shown by the matched 
pair of compounds 36 and 37, where a methyl group 
replaced a hydrogen bond donor and markedly reduced 
activity against Nek2 but not CDK2. Increasing the size 
of the di-substituted amides decreased Nek2 activity 
further whilst retaining modest CDK2 activity (e.g. 
38), indicating that hydrophobic interactions may be 
particularly unfavourable for Nek2 inhibitory activity in 
this region. A similar decrease in potency was observed 
for Nek2 and CDK2 (~2-fold) when the size of the 
alkyl ring of cyclic secondary amides was increased 
(35 and 36). Compound 15 possesses the amide NH 
hydrogen bond donor but had a higher potency against 
CDK2. Replacing the methyl group of 15 with n-propyl 
(39) reduced activity against Nek2 whilst maintaining 
CDK2 inhibition. The iso-butyl analogue (34) was also 
less active against Nek2 than 15 but equipotent to 39, 
indicating that the Nek2 active site is sterically limited. 
Scheme 5: Synthesis of 6-(dialkylamino)vinyl-purines.a a Reagents and conditions: (a) RR′NH, THF, microwave 100 °C, 10 min, 
60 – 98% (Supplementary Table S1).
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Table 2: Inhibition of CDK2 and Nek2 by representative 2-arylamino-O6-cyclohexylmethylpurines.a
Compound Sub-structure R
IC50 (μM) / % 
inhibition Compound Sub-structure R
IC50 (μM) / % 
inhibition
Nek2 CDK2 Nek2 CDK2
8 A CONH2 19 0.48 35 C 4.1 1.1
10 A CONHCH3 15 0.83 36 C 8.4 2.1
11 A CON(CH3)2 0.62 7.0 37 C
26% @ 50 
μM
1.6
12 A 5.2 5.7 38 C CON(i-Pr)2 21 3.2
13 A 46% @ 50 
μM
0.33 39 C CONH-n-Pr 82% @ 50 
μM
0.74
14 A SO2N(CH3)2
40% @ 50 
μM
3.5 40 C 1.3 0.8
15 C CONHCH3 1.3 0.32 41 C 6.13 1.6
16 B 2.2 1.1 42 C 0.28 1.0
17 B 1.1 0.86 43 C 1.0 0.59
18 B 1.2 0.72 44 C 29% @ 50 
μM
3.7
23 A CO2H 4.3 0.99 45 C 0.7 0.86
27 A NHCOMe 8.3 0.88 46 C 3.6 2.4
28 B NHCOtBu 24 9.7 47 C Inactive 10
29 B NHCOPh 36% at 50 
μM
2.9 48 C SO2N(Me)2 0.83 0.77
30 B 51% at 50 
μM
2.2 49 C 53% @ 50 
μM
1.6
(Continued )
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In contrast, the effect on CDK2 inhibition was limited 
(IC50 values ranging from 0.3-0.9 μM).
Introducing a terminal hydroxy group on the 
propyl chain (40) was tolerated for Nek2 inhibition, 
and a dimethylamino group (42) at the end of the propyl 
side chain increased activity against Nek2. Shortening 
the alkyl chain of 42 from propyl to ethyl (43) did not 
improve Nek2 inhibition, and removal of the amino 
functionality of 43 to give 44 greatly reduced Nek2 
inhibition, suggesting that the basicity of the tertiary 
amino group was required. In summary, these results 
indicated the possibility of an additional interaction in 
the Nek2 binding site for a basic moiety at the end of 
the propyl chain.
Selectivity for CDK2 over Nek2 was observed for 
the sulfonamides shown in Table 2  with the exception 
of 48, which was equipotent against both CDK2 and 
Nek2. The primary sulfonamide 53 exhibited good 
potency against CDK2 and some activity against Nek2. 
Cyclic secondary sulfonamides (e.g. 49) were essentially 
inactive against Nek2 except for heterocyclic derivatives 
(e.g. 50), which showed modest activity against Nek2. 
Nevertheless, all of the sulfonamides tested were more 
potent against CDK2 than Nek2. Inhibition of Nek2 
by 50 could be attributed to the basic properties of the 
piperidine ring, which appears to be favourable for 
Nek2 activity. Compound 49 supports this observation 
given its lower activity against Nek2. Larger lipophilic 
substituents (e.g. 52) resulted in greatly decreased 
activity against Nek2 and variable effects on CDK2 
activity. In comparison to the most potent carboxamide 
(42) the corresponding sulfonamide (51) was both less 
active (5-fold) and less selective for Nek2.
The urea moiety was also investigated as a putative 
non-classical isosteric replacement for the sulfonamide 
functional group. 6-Alkoxy-2-arylaminopurines with urea-
based side-chains exhibited low-micromolar activity against 
Nek2, as compared to micromolar or sub-micromolar 
inhibition of CDK2; as exemplified by 16 (Nek2 IC50 = 
2.2 μM, CDK2 IC50 = 1.1 μM). Disappointingly, primary 
ureas e.g. 31 were found to be 10-fold selective for 
CDK2 over Nek2. Elaboration of this group bysynthesis 
of secondary ureas e.g. N-ethylmorpholine derivative 16, 
enhanced activity against Nek2. Replacement of the N-
ethyl-morpholino group by e.g. N-ethyl-piperidine (17) and 
dimethylaminopropyl (18) side-chains, did not greatly affect 
inhibition or selectivity profile for Nek2 or CDK2. These 
results suggest that whilst, potency against Nek2 may be 
gained from incorporation of a basic group and a donor-
acceptor moiety at the 2-arylamino position, the additional 
hydrogen-bond acceptor in the morpholine is unnecessary 
or even detrimental.
Modifications at the purine 6-position
In order to improve potency against Nek2 whilst 
retaining the selectivity observed within some examples 
from the homocarboxamide series e.g. 42, alternative 
substitution at the 6-position was investigated (Table 3). 
In comparison to 42, selectivity for Nek2 over CDK2 was 
maintained by combining an O6-ethyl substituent with 
the dimethylaminopropyl homocarboxamide side chain 
(59;CDK2 IC50 = 5.6 μM; Nek2 IC50 = 0.89 μM), albeit 
with some loss of potency against both kinases. Imidazole 
derivative 62 exhibited 2-fold improved Nek2 inhibitory 
activity combined with a 2-fold reduction in CDK2 
inhibition, compared with the analogous cyclohexylmethyl 
derivative 41. Interestingly, the O6-sec-butyl derivative 
with a N,N'-dimethylaminopropyl side chain 60 gained 
potency against CDK2 with 10-fold selectivity over Nek2.
Guanine derivatives lacking the O-alkyl substituent 
(65 and 67) exhibited a dramatic reduction in potency 
against CDK2 compared with the parent 6-alkoxy 
Compound Sub-structure R
IC50 (μM) / % 
inhibition Compound Sub-structure R
IC50 (μM) / % 
inhibition
Nek2 CDK2 Nek2 CDK2
31 A 3.6 0.38 50 C 2.6 0.45
32 A 57% @ 50 
μM
18 51 C 1.42 0.53
33 A 3.8 0.73 52 C 38% @ 100 
μM
3.0
34 C 79% @ 50 
μM
0.94 53 C SO2NH2
81% @ 50 
μM
0.24
All IC50 values are results obtained from n = 3 determinations. 
aSee also Supplementary Table S3 (ESI) for complete 
compound data. bNek2 Caliper assay conducted at 30 μM ATP concentration – full details in reference 12. cCDK2 assay 
conducted at 12.5 μM – full details in reference 20.
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compounds, yet Nek2 inhibition was maintained. The 
6-unsubstituted purine derivative bearing a substituted 
urea side-chain (65)was approximately 4-fold less potent 
against Nek2 than the parent 6-alkoxypurine 17 but, 
importantly, gave only 30% inhibition of CDK2 at 100 
μM. Activity against Nek2 was also maintained for the 
6-unsubstituted imidazole homocarboxamide purine (67), 
and CDK2 inhibitory activity was again abolished. This 
result indicated that a 6-cyclohexylmethyl substituent 
conferred potent CDK2 inhibition but was not necessary 
for Nek2 inhibition. A significant improvement in 
selectivity was gained as a result of this modification, 
confirming that there are exploitable differences between 
the ribose-binding pockets of Nek2 and CDK2.
Having generated a series of enamines to probe 
the replacement of the O6-alkoxy substituent, SARs 
revealed that polar substituents, e.g. morpholine (see 
ESI), and hydrophobic alkyl substituents such as those in 
compounds 69-71 were tolerated. Larger cyclic secondary 
amines such as homopiperidine (72) were found to be 
sub-micromolar inhibitors of Nek2 (IC50 = 0.27 μM). 
However, the addition of a second basic group as in 
3-dimethylaminopyrrolidine (73) reduced the inhibition 
of Nek2 around 10-fold as compared with 69. The 
CDK2 counter-screening data were largely unremarkable 
as the compounds 69-73 were only low-micromolar 
CDK2 inhibitors with the exception of the diethylamino 
compound 71 (IC50 = 0.65 μM). From the data obtained, 
it appeared that the most potent enamine-based Nek2 
inhibitors were generally also more potent against CDK2. 
To assess the broader kinase selectivity of this series of 
6-(dialkylamino)vinyl-purines, the diethylamino derivative 
71 was chosen for wider screening against 24 kinases at 
2 μM inhibitor concentration (Figure 5 – method as in 
reference 12). Compound 71 did not significantly inhibit 
other kinases studied with the exception of the mitotic 
kinases aurora A (100% inhibition at 2 μM) and Chk2 
(65% at 2 μM). If 71 is representative of the entire 
series, this may indicate a lack of selectivity for Nek2. 
In a separate counter-screen, dimethylamino derivative 70 
was found to inhibit weakly another mitotic kinase, Plk1 
(41% at 10 μM – method as in reference 12). Cell growth 
inhibition studies (Figure 6) with compounds 69-73 in 
human tumor cell lines, including U2OS, MDA-MB-231 
and HeLa cells, showed modest effects on cell viability 
(GI50 > 10 μM). Interestingly, the cellular activity did not 
reflect the relative potencies in the Nek2 kinase assay and 
may indicate that cell growth inhibition is due to inhibition 
of a combination of Nek2 and other kinases e.g. aurora A.
A representative enamine (70) was shown not to 
exhibit time-dependent Nek2 inhibition kinetics (Figure 
7A (see also ESI), indicating that the compound binds 
reversibly to Nek2 and that the enamine is not chemically 
reactive within the Nek2 active site. This observation was 
also confirmed by kinetic studies of kinase inhibition, 
which showed that removal of the inhibitor by rapid 
dilution of the assay medium, restored kinase activity 
(Figure 7B) [33].
Structural biology studies confirmed that the 
6-(2-aminovinyl)purine Nek2 inhibitors occupied a 
binding orientation nearly identical to that of the O6-
alkylpurines. The interactions between the purine and the 
kinase hinge motif were clearly visible (Figure 8A) and 
the enamine 6-substituent was shown to point towards 
the hydrophobic glycine-rich loop (Figure 8B), which is 
consistent with the O6-alkyl purine hits from the initial 
screening results.
Figure 4: Crystal structure of carboxamide 11 (cyan) bound to the T175A Nek2 mutant (carbon atoms are coloured 
yellow, oxygen coloured red, and nitrogen coloured blue). Hydrogen bonds are represented as dotted lines and important residues 
are highlighted.
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Stability of enamines
To determine whether the enamines were hydrolysed 
under the assay conditions, the stability of representative 
enamine derivative 72 was assessed in a range of assay 
media and pH buffers. Stock solutions of 72 in each of the 
various media were prepared and aliquots were extracted 
from each solution at various time points and subjected to 
HPLC analysis to measure the remaining intact enamine 
(Figure 9).
In two different standard assay media (MEM and 
RPMI, Figure 9A) enamine 72 was degraded at a similar 
rate. Addition of 10% foetal calf serum (FCS) to the media 
caused no difference in the observed stability, suggesting 
that breakdown was independent of the composition of 
the media and was non-enzymatic. The lack of enzymatic 
involvement in the breakdown was confirmed by 
incubation of 72 in protein solutions (Figure 9B). Similar 
rates of decomposition of 72 were observed in media 
Table 3: Nek2 and CDK2 inhibition by selected 6-unsubstituted and 6-substituted purines. a
Compound R1 R2 IC50 (μM) or % inhibition
Nek2
(30 μM ATP) a
CDK2
(12.5 μM ATP)b
59 OEt 0.89 5.6
60 4.9 0.41
62 OEt 2.8 5.2
65 H 4.5 30% @ 100 μM
67 H 5.9 >100
69 0.34 5.8
70 0.77 3.0
71 0.24 0.65
72 0.27 2.7
73 3.0 6.9
All IC50 values are results obtained from n = 3 determinations. 
asee also Supplementary Table S2 (ESI) for complete 
compound data. bNek2 Caliper assay conducted at 30 μM ATP concentration – full details in reference 12. cCDK2 assay 
conducted at 12.5 μM – full details in in reference 20.
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containing FCS and water containing FCS, both of which 
contained active enzymes, compared with solutions of 
boiled (inactivated) FCS in water. A surprising result was 
that 72 was relatively stable over a period of 24 hours 
in human plasma, potentially reflecting the impact of 
reversible plasma protein binding. Whilst, the enamine 72 
was stable in DMSO solutions for over 24 h and relatively 
stable at pH 2.2, under neutral (pH 7) and basic (pH 10.4) 
conditions the enamine 72 was rapidly degraded (Figure 
9C), contrary to the expected profile. Together, these 
stability observations suggest that the enamine motif 
is relatively unstable under model conditions, which 
are similar to those used for the cell-based assays. This 
may explain the mostly flat SARs observed in cellular 
assays for this series, perhaps due to the enamine group 
degradation to a reactive aldehyde, which is a hydrolysis 
Figure 5: Counter-screening of 71 against a panel of kinases.
Figure 6: Growth inhibition (GI50) of selected cell-lines by enamines 69-73.
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Figure 7: Mechanism of action studies with enamine 70. A. The effect of pre-incubation (2-60 min) of Nek2 with 70 on inhibitory 
potency. B. Reversibility studies indicating that 70 was not an irreversible inhibitor of Nek2 (Supplementary Table S4).
Figure 8: Crystal structures of compound 71 in complex with Nek2. A. Interaction of 6-(2-aminovinyl)purine derivative 71 
(carbon atoms coloured orange) with the hinge region of Nek2. B. Orientation of the C-6 substituents towards the glycine-rich loop.
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product common to all members of this series. Some 
notable differential activity is noted, however, and may 
be attributed to varying rates of enamine hydrolysis to 
the corresponding aldehyde more or less quickly than 
72. Reduction of the enamine to the corresponding 
tertiary amine may provide a possible solution to stability 
problems.
Structural insights into Nek2 activation
To gain an insight in to the molecular mechanisms 
of Nek2 activation, structural biology studies were 
conducted using Nek2 in complex with carboxamide 
11, which was one of the newly synthessied inhibitors 
with the greatest Nek2-selectivity profile (Table 2). In 
complex with purine-based ATP-competitive inhibitors, it 
has been previously shown that Nek2 adopts an inactive 
conformation characterized by a partially disordered 
activation loop and an outward position of the αC-helix 
(Figure 10A). This is similar to that observed in previously 
determined Nek2 structures such as the complex with ADP 
(Figure 10B) [34]. Here, in complex with carboxamide 11, 
and in contrast to previous structures, the activation loop 
of Nek2 has a DFG-in conformation, indicating that 11 
is the first reported inhibitor of Nek2 to function in this 
way. The phenylalanine (Phe-160 in Nek2) of the DFG 
motif is one of the four regulatory (R-) spine residues, 
which adopt a continuous hydrophobic column in active 
kinases (Figure 10C) [35]. The DFG-in conformation is 
required to form the R-spine. The HRD motif also adopts 
the position expected in an active kinase structure and 
thus, in the presence of 11, Nek2 has a more ordered 
R-spine. However, one of the four R-spine residues is out 
of position compared to that expected in an active kinase 
because the αC-helix is in an αC-out position.
The conformation adopted here by Nek2 appears to 
be stabilized by 11. The clearest connection here is the 
interaction of the ligand with Lys-37, which is connected 
to the DFG motif through an interaction with the side 
chain of Asp-159. The conformations of the DFG and 
HRD motifs are coupled through aromatic stacking 
between the side chains of Phe-160 and His-139. Thus, 
the purine scaffold induces a specific conformation of key 
structural elements of Nek2 through a network of H-bond 
interactions.
The crystal structure of Nek2 bound to purine 
compounds suggests an intermediate state of a kinase 
poised for activity, and we propose a stepwise pathway 
for Nek2 activation (Figure 10D). Unphosphorylated 
Nek2 is in an autoinhibited state, in which the activation 
Figure 9: Stability of 72 in various assay media. BSA (bovine serum albumin) and FCS. Note: MEM (minimum essential medium) 
and RPMI (Roswell Park Memorial Institute) media contain no proteins or enzymes.
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loop forms an α-helix (αT) that stabilizes the outwards 
position of the αC-helix and blocks formation of an 
R-spine. Refolding of αT by formation of a DFG-
in conformation of the activation loop is coupled to 
changes in the HRD motif that results in a partially 
formed R-spine and a disordered activation loop. In this 
pre-active state the outward location of the αC-helix is 
destabilized and the activation loop is disordered. The 
kinase may have sufficient flexibility to transiently adopt 
an active state necessary for autophosphorylation. Nek2 
autophosphorylation is expected to result in a fully-active 
conformation of the kinase with a fully-assembled R-spine 
and an ordered activation loop. In our study, the pre-active 
state of Nek2 was induced by ATP-competitive inhibitors 
based on a purine scaffold (i.e. carboxamide 11). In a 
physiological context, it is likely that Nek2 activation is 
promoted by protein-protein interactions, such as Nek2 
dimerization.
In crystal structures of Nek2 bound to purine 
inhibitors, the region C-terminal to the αE helix and 
N-terminal to the HRD motif is ordered (Figure 11A), 
unlike other structures of Nek2 (Figure 11B). The loop 
structure contacts the αC-helix in the N-lobe of the protein 
and occupies the equivalent space as the activatory helix 
of TPX2 in the Aurora-A/TPX2 complex (Figure 11C). 
Based on these observations, we predict that this loop will 
fulfill a similar role in the stabilization of the activation 
loop in the active Nek2 structure. This loop is not present 
in other Neks and is indeed unique to Nek2 among human 
kinases (Figure 11D). Importantly, targeting this unique 
protein conformation with small molecules presents an 
attractive opportunioty for selective inhibition of Nek2 
over other kinome members.
In conclusion, a number of key structural 
requirements for selective Nek2 inhibition over CDK2 
have been elucidated by synthesis and evaluation of 
purines probes bearing informative modifications, 
specifically at the 2-arylamino and 6-positions. These 
significantly include the importance of a terminal 
basic group, especially the NMe2 residue, on the meta-
Figure 10: Purine ATP-competitive inhibitors induce a pre-active, DFG-in, αC-out conformation of Nek2. A. Crystal 
structure of Nek2 in complex with compound 11. B. Crystal structure of Nek2 in complex with ADP (PDB code 2W5A). C. Crystal structure 
of active Aurora-A (PDB code 2W5A). In panels A-C, hydrophobic R-spine residues are coloured magenta. D. Schematic illustration of 
activation pathway of Nek2.
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substituent of 2-arylamino derivatives which consistently 
showed good potency when incorporated into (homo)
sulfonamide, (homo) carboxamide and urea sidechains. It 
was also noteworthy that a hydrogen bond donor-acceptor 
group, e.g. urea, played a role in potent Nek2 inhibition, 
whilst sulfonamides may confer CDK2 inhibitory activity 
due to interactions previously reported [32]. It may also be 
concluded that para-substitution on the 2-arylamino ring 
may be preferable for CDK2 inhibition, whereas meta-
substitution generally affords lower CDK2 inhibitory 
activities, and in some cases improved Nek2 inhibition.
Aided by structural biology, we have shown that it 
may be possible to obtain further selectivity by removal of 
the O6-cyclohexylmethyl group, which abolished CDK2 
inhibition but was not essential for Nek2 inhibition. 
A facile and rapid synthesis of 6-(dialkylaminovinyl)
purines was described and such groups at the purine 
6-position conferred potent Nek2 inhibition and a 
degree of kinase selectivity. Subsequently, it has been 
found that the precursor of these enamines, 6-ethynyl-
2-phenylaminopurine 68, reacts covalently with Cys-
22 of Nek2, thus behaving as an irreversible inhibitor. 
Identification and structure-activity relationships for 
2-arylamino-6-ethynylpurines as irreversible inhibitors of 
Nek2 kinase will be the subject of our next publication.
Crystal structures of Nek2 in complex with purines 
e.g. carboxamide 11 provide a snapshot of Nek2 in a 
conformation closer to that of an active kinase than was 
observed in previous Nek2 structures. This provides a 
potentially unique and selective molecular target for 
small molecule kinase inhibition. Moving forward, the 
development of tool compounds with improved potency 
and selectivity will be required in future studies to assist 
with target validation, cellular studies and to understand 
better the role of Nek2 in mitosis and cancer.
Figure 11: Nek2 has a unique insertion N-terminal to the ‘HRD’ motif. A. Crystal structure of Nek2 in complex with compound 
11. B. Crystal structure of Nek2 in complex with ADP (PDB code 2W5A). C. Crystal structure of active Aurora-A (PDB code 2W5A). D. 
Sequence alignment of human Neks in the vicinity of the ‘HRD’ motif, showing the insert sequence that is unique to Nek2.
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MATERIALS AND METHODS
Synthetic chemistry
All chemicals were purchased from standard 
suppliers. Solvents were purified and stored according 
to standard procedures. Melting points were obtained on 
a Stuart Scientific SMP3 apparatus and are uncorrected. 
TLC was performed with Merck 60 F254 silica gel 
plates. Where appropriate, compound mixtures were 
separated and purified using either medium pressure 
(‘flash’) chromatography, employing Davisil silica 40-60 
μm, or using a Biotage SP4 automated chromatography 
system with UV monitoring at 254 and 290 nm. When 
using the Biotage SP4 to purify samples, the stationary 
phase was KP-SIL (silica), Biotage KP-NH or KP-C18 as 
appropriate. 12+M, 25+M or 40+M pre-packed columns 
were used as required. KP-NH was used for the normal-
phase purification of polar organic amines. KP-C18 (18% 
carbon by weight) was used for the separation of polar 
and ionisable organic compounds, requiring a water-based 
eluent and lipophilic stationary phase. 1H NMR and 13C 
NMRspectra were recorded on a Bruker Spectrospin AC 
300E spectrometer (300 MHz for 1H, 75 MHz for 13C) 
or a Bruker AMX (500 MHz for 1H, 126 MHz for 13C). 
Samples were acquired in deuterated solvents including 
CDCl3 and DMSO-d6. Where appropriate (compounds 69-
73), reactions were carried out with microwave heating, in 
sealed vessels, using a Biotage Initiator reactor equipped 
with a ‘Sixty robot’. Samples were irradiated at 2.45 GHz, 
reaching temperatures from 60-250 ºC (rate of heating 2-5 
°C/sec) and pressures up to 20 bars. LCMS was carried 
out on either a Micromass Platform instrument operating 
in positive and negative ion electrospray mode, employing 
a 50 x 4.6 mm C18 column (Supelco Discovery or Waters 
Symmetry) and a 15 min gradient elution of 0.05% formic 
acid and methanol (10-90%), or on a Finnegan LCQ 
instrument in positive ion mode with a Phenomenex 5μ 
Luna C18 column, 4.6 mm x 50 mm and an 8 min gradient 
of 0.1% aqueous formic acid and acetonitrile (5-98%), 
with a flow rate of 2 mL/min. IR spectra were recorded 
on a Bio-Rad FTS 3000MX diamond ATR. HRMS were 
measured using a Finnigan MAT 95 XP or a Finnigan 
MAT 900 XLT by the EPSRC National Mass Spectrometry 
Service Centre (Swansea).
Synthesis of 2-arylaminopurines (compounds 8, 10-26, 
59-61, 65, 66). Method I. General Procedure
To a stirred suspension of the appropriate 2-fluoro-
9H-purine (0.49 mmol) and the required aniline derivative 
(0.98 mmol) in TFE (25 mL/g of fluoropurine) was added 
TFA (0.19 mL, 2.46 mmol) dropwise. The resulting 
solution was heated under reflux for 48 h under a nitrogen 
atmosphere. The solvent was removed in vacuo and the 
residue was redissolved in EtOAc (10 mL). The solution 
was washed several times with saturated NaHCO3 solution 
(3 × 10 mL), and the aqueous extracts were combined 
and washed with EtOAc (10 mL). The combined organic 
layers were dried (Na2SO4) and the solvent was removed 
to give a residue that was purified as indicated.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
benzamide (8)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine (9, 
125 mg, 0.50 mmol) and 3-aminobenzamide (136 mg, 
1.0 mmol), TFE (5 mL), and TFA (0.19 mL, 2.5 mmol). 
The crude product was dry-loaded onto silica (~30 mL) 
and purified by column chromatography (eluent: EtOAc) 
to give a light brown powder, (62 mg, 34%): Rf = 0.18 
(MeOH-EtOAc; 1:9); mp 231-232 °C; IR (cm-1) 3350, 
2922, 2851, 2160, 1577, 1541, 1118; 1H NMR (300 MHz, 
DMSO-d6) δ 0.85-1.70 (11H, m, cyclohexyl), 4.36 (2H, d, 
J = 5.4 Hz, OCH2), 7.24-7.34 (2H, m, 2 × ArH), 7.39 (1H, 
d, J = 8.4 Hz, ArH), 7.85 (2H, s, CONH2), 7.99 (1H, s, 
H-8),8.37 (1H, s, ArH), 9.43 (1H, s, ArNHAr), 12.83 (1H, 
s br, N9-H); 13C NMR (75 MHz, DMSO-d6) δ 25.6, 26.4, 
29.6, 37.4, 71.6, 97.0, 114.4, 118.7, 120.2, 121.6, 128.4, 
135.5, 141.9, 155.8, 169.0; LCMS (ES+) m/z 367 [M+H]+; 
HRMS (ES+) calcd for C19H23N6O2 [M+H]
+ 367.1877, 
found 367.1875; λmax (EtOH) 273, 293 nm.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N-
methylbenzamide (10)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine (9, 
75 mg, 0.30 mmol), 3-amino-N-methylbenzamide (see 
ESI S3; 102 mg, 0.68 mmol), TFE (3 mL), and TFA (0.11 
mL, 1.5 mmol). The crude product was allowed to stand in 
DCM (20 mL) for 2 h at room temperature. The resulting 
precipitate was filtered and washed with DCM (2 × 5 mL) 
to give the title compound as a pale pink solid (88 mg, 
77%): Rf = 0.10 (EtOAc); mp 252-254 °C; IR (cm
-1) 3257, 
3061, 2928, 2854, 1638, 1612, 1579, 1538, 1485, 1446, 
1381, 1257; 1H NMR (300 MHz, DMSO-d6) δ 1.0–1.84 
(11H, m, cyclohexyl), 2.77 (3H, d, J = 4.4 Hz, NHCH3), 
4.35 (2H, d, J = 6.1 Hz, OCH2), 7.32 (2H, m, 2 × ArH), 
7.85 (1H, br, CONH), 7.98 (1H, s, ArH), 8.27-8.35 (2H, 
m, ArH and H-8), 9.45 (1H, s, ArNHAr), 12.83 (1H, s, 
N9-H); LCMS (ES+) m/z 381.45 [M+H]+; HRMS (ES+) 
calcd for C20H25N6O2 [M+H]
+ 381.2034, found 381.2034; 
λmax (EtOH) 273 nm.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-
dimethylbenzamide (11)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine (9, 
80 mg, 0.32 mmol), 3-amino-N,N-dimethylbenzamide (see 
ESI S4; 105 mg, 0.64 mmol), TFE (4 mL), and TFA (0.12 
mL, 1.6 mmol). The crude product was dry-loaded onto 
silica and purified by column chromatography (EtOAc-
petrol; 9:1) to give an off-white powder (68 mg, 54%): Rf 
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= 0.09 (EtOAc); mp 120-121 °C; IR (cm-1) 3266, 2922, 
2849, 1973, 1581, 1435, 1386; 1H NMR (300 MHz, 
DMSO-d6) δ 0.95-1.80 (11H, m, cyclohexyl), 2.95 (6H, 
s, N(CH3)2), 4.33 (2H, d, J = 6.3 Hz, OCH2), 6.90 (1H, 
d, J = 7.6 Hz, ArH), 7.31 (1H, dd, J = 7.8, 8.0 Hz, ArH), 
7.77 (1H, d, J = 8.1 Hz, ArH), 7.98 (1H, s, ArH), 8.03 
(1H, s, H-8), 9.45 (1H, s, ArNHAr), 12.91 (1H, s, N9-H); 
13C NMR (75 MHz, DMSO-d6) δ 25.6, 26.4, 29.6, 37.3, 
71.5, 114.1, 116.93, 119.3, 119.4, 128.6, 137.3, 140.2, 
141.6, 155.6, 160.0, 170.8; LCMS (ES+) m/z 395 [M+H]+; 
HRMS (ES+) calcd for C21H27N6O2 [M+H]
+ 395.2190, 
found 395.2189; λmax (EtOH) 272, 295 nm.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-
dimethylthiobenzamide (12)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine (9, 
88 mg, 0.35 mmol), 3-amino-N,N-dimethylthiobenzamide 
(see ESI S7; 140 mg, 0.78 mmol), TFE (3 mL), and TFA 
(0.13 mL, 1.8 mmol). The crude product was dry-loaded 
onto silica (4 mL) and purified by column chromatography 
(EtOAc-petrol; 7:3) followed by further purification by 
semi-prep HPLC (mobile phase A – eluted with 40% 
acetonitrile, flow-rate 12.75 mL/min, wavelength 280 
nm) to give the title compound as a yellow solid (35 mg, 
24%): Rf = 0.18 (EtOAc-petrol; 7:3); mp 231-232 °C 
(dec.); IR (cm-1) 2926, 2851, 1629, 1580, 1521, 1487, 
1431, 1393, 1258, 1116; 1H NMR (300 MHz, DMSO-
d6) δ 0.9-1.7 (11H, m, cyclohexyl), 3.17 (3H, s, NCH3), 
3.50 (3H, s, NCH3), 4.33 (2H, d, J = 6.1 Hz, OCH2), 6.78 
(1H, d, J = 7.4 Hz, ArH), 7.26 (1H, dd, J = 7.9, 7.9 Hz, 
ArH), 7.66 (1H, d, J = 7.7 Hz, ArH), 7.90 (1H, s, ArH), 
8.01 (1H, s, H-8), 9.45 (1H, s, ArNHAr), 12.72 (1H, s br, 
N9-H); LCMS (ES+) m/z 411 [M+H]+; HRMS (ES+) calcd 
for C21H27N6OS [M+H]
+ 411.1962, found 411.1959; λmax 
(EtOH) 236, 277 nm.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
thiobenzamide (13)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine (9, 
75 mg, 0.3 mmol), 3-aminothiobenzamide (see ESI S8; 
92 mg, 0.6 mmol), TFE (3 mL), and TFA (0.11 mL, 1.5 
mmol). The crude product was dry-loaded onto silica (4 
mL) and purified by column chromatography (EtOAc-
petrol; 7:3 up to EtOAc) followed by further purification 
by semi-prep HPLC (5 → 100% v/v acetonitrile: water: 
NH4OH over 25 min; flow-rate 12.75 mL/min, wavelength 
280 nm) to give the title compound as a yellow solid (37 
mg, 32%): Rf = 0.28 (EtOAc-petrol; 9:1); mp 148-149 
°C (dec.); IR (cm-1) 3271, 3077, 2920, 2849, 2363, 2337, 
1597, 1537, 1483, 1438, 1391, 1352, 1319, 1283, 1117, 
973; 1H NMR (300 MHz, DMSO-d6) δ 1.00-1.90 (11H, m, 
cyclohexyl), 4.37 (2H, d, J = 5.8 Hz, OCH2), 7.29 (2H, d, 
J = 7.3 Hz, ArH), 7.79 (1H, d, J = 7.3 Hz, ArH), 7.98 (1H, 
s, H-8), 8.44 (1H, s, ArH), 9.43 (2H, br, NH2), 9.82 (1H, 
s, ArNHAr), 12.81 (1H, s br, N9-H); 13C NMR (125 MHz, 
DMSO-d6) δ 25.2, 26.0, 29.2, 36. 9, 71.2, 114.9, 118.2, 
118.8, 120.9, 127.8, 139.0, 140.7, 140.7, 154.2, 155.3, 
160.1, 201.1; LCMS (ES+) m/z 411 [M+H]+; HRMS (ES+) 
calcd for C19H23N6OS [M+H]
+ 383.1649, found 383.1647; 
λmax (EtOH) 278, 295 nm.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-
dimethylbenzenesulfonamide (14)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine 
(9,75 mg, 0.30 mmol), 3-amino-N,N-
dimethylbenzenesulfonamide (see ESI S10; 136 mg, 0.68 
mmol), TFE (3 mL), and TFA (0.11 mL, 1.5 mmol). After 
concentration in vacuo, the residual oil was extracted 
into DCM (10 mL) and cooled to 0 °C overnight. The 
resulting precipitate was collected by filtration under 
vacuum, washed with DCM (10 mL) and dried (Na2SO4) 
to give the title compound as an off-white solid (35 mg, 
27%): Rf= 0.54 (EtOAc); mp 143-145 °C; IR (cm
-1) 2926, 
2850, 1598, 1579, 1543, 1433, 1394, 1334, 1249, 1149, 
951; 1H NMR (300 MHz, DMSO-d6) δ 1.2-1.9 (11H, m, 
cyclohexyl), 2.64 (6H, s, N(CH3)2, 4.36 (2H, d, J = 6.2 
Hz, OCH2), 7.24 (1H, d, J = 7.5 Hz, ArH), 7.52 (1H, dd, 
J = 8.0, 8.0 Hz, ArH), 7.96 (1H, d, J = 7.4 Hz, ArH), 8.04 
(1H, s, H-8), 8.50 (1H, s, ArH), 9.77 (1H, s, ArNHAr), 
12.89 (1H, s, N9-H); 13C NMR (125 MHz, DMSO-d6) 
δ 25.2, 26.0, 29.2, 36.9, 37.7, 71.3, 116.2, 119.1, 122.0, 
129.3, 134.9, 142.0, 154.9; LCMS (ES+) m/z 431 [M+H]+; 
Anal. calcd for C20H26N6O3: C, 55.80; H, 6.09; N, 19.52%; 
found: C, 55.77; H, 6.00; N, 19.47; λmax (EtOH) 275, 293 
nm.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylanilino]-N-
methylacetamide (15)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine 
(9, 75 mg, 0.30 mmol), 2-(3-aminophenyl)-N-
methylacetamide (see ESI S12; 98 mg, 0.60 mmol), 
TFE (3 mL), and TFA (0.11 mL, 1.5 mmol). The crude 
product was adsorbed onto silica gel (~3 mL) and purified 
by column chromatography (eluent: 5% MeOH/ EtOAc) 
and HPLC to give an off-white powder (53 mg, 45%): Rf 
= 0.23 (MeOH-EtOAc; 1:9); mp 176-177 °C; IR (cm-1) 
3267, 2921, 2850, 2362, 2160, 2013, 1587, 1499, 1396, 
1346, 1239, 1119; 1H NMR (300 MHz, DMSO-d6) δ 
1.0–1.8 (11H, m, cyclohexyl), 2.50 (3H, d, J = 4.6 Hz, 
NCH3), 4.26 (2H, d, J = 6.3 Hz, OCH2), 6.74 (1H, d, J = 
7.6 Hz, ArH), 7.10 (1H, dd, J = 7.8, 7.9 Hz, ArH), 7.56 
(1H, s, ArH), 7.62 (1H, d, J = 8.2 Hz, ArH), 7.85 (1H, 
q, J = 4.6 Hz, CONH), 7.96 (1H, s, H-8), 9.21 (1H, s, 
ArNHAr), 12.68 (1H, br, N9-H); 13C NMR (75 MHz, 
DMSO-d6) δ 25.6, 26.0, 26.4, 29.6, 37.3, 43.1, 44.5, 71.5, 
117.2, 119.9, 122.0, 128.4, 134.6, 136.8, 139.8, 141.4, 
156.0, 170.8; LCMS (ES+) m/z 395 [M + H]+; Anal. calcd 
for C21H26N6O2: C, 63.94; H, 6.64; N, 21.31%; found: C, 
63.80; H, 6.85; N, 20.97; λmax (EtOH) 207.0, 271.5, 293.5 
nm.
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1-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)
phenyl)-3-(2-morpholinoethyl)urea (16)
Following Method I, the title compound was 
prepared using 6-(cyclohexylmethoxy)-2-fluoro-9H-
purine (9) (0.15 g, 0.59 mmol) and 1-(4-aminophenyl)-
3-(2-morpholinoethyl) urea (see ESI S18; 0.31 g, 1.17 
mmol) and TFA (0.27 mL, 3.5 mmol) in TFE (6.0 mL). 
The compound was purified by recrystallisation from 
EtOAc to obtain a white solid (50 mg, 17%): mp 161-163 
ºC; IR (cm-1) 3134, 2849, 2812, 1634 υ(NN'C=O), 1558, 
1506; 1H NMR (300 MHz, DMSO-d6) δ 1.12-1.42 (5H, m, 
cyclohexyl), 1.78-1.99 (6H, m, cyclohexyl), 2.54 (6H, m, 
N(CH2)3), 3.38 (2H, dt, J = 6.0, 12.0 Hz, CH2), 3.73 (4H, 
t, J = 4.5 Hz, OCH2 morpholine), 4.37 (2H, d, J = 6.0 
Hz, OCH2), 7.21 (2H, d, J = 8.5 Hz, H-2' and H-6'), 7.67 
(2H, d, J = 8.5 Hz, H-3' and H-5'), 7.92 (1H, s, H-8); 13C 
NMR (75 MHz, DMSO-d6) δ 27.3, 28.1, 31.2, 36.4, 39.1, 
54.1, 59.4, 68.1, 73.3, 115.1, 121.4, 121.6, 123.0, 135.2, 
137.9, 151.1, 151.9, 158.0, 159.1; LCMS (ES+) m/z 495.1 
[M+H]+; λmax (EtOH) 280.0, 238.0 nm.
1-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)
phenyl)-3-(2-(piperidin-1-yl)ethyl)urea (17)
Following Method I, the title compound was 
prepared using 6-(cyclohexylmethoxy)-2-fluoro-9H-
purine (9, 0.15 g, 0.59 mmol) and 1-(4-aminophenyl)-
3-(2-(piperidin-1-yl)ethyl)urea (see ESI S20; 0.30 g, 
1.17 mmol) and TFA (0.27 mL, 3.5 mmol) in TFE (4 
mL). The compound was purified using the Biotage 
SP4 chromatography (KP-NH; MeOH-EtOAc; 1:9) to 
obtain the desired compound as an off-white solid (0.14 
g, 48%): mp 158-160 ºC; IR (cm-1) 2924, 2849, 1644 
υ(NN'C=O), 1610, 1556, 1506; 1H NMR (300 MHz, 
DMSO-d6) δ 1.10-1.19 (5H, m, cyclohexyl), 1.48-1.55 
(6H, m, CH2 piperidine), 1.76-1.84 (6H, m, cyclohexyl), 
3.17 (2H, m, CH2), 2.33 (6H, m, N(CH2)3), 4.30 (2H, d, 
J = 6.0 Hz, OCH2), 7.27 (2H, d, J = 8.0 Hz, H-2' and 
H-6'), 7.62 (2H, d, J = 8.0 Hz, H-3' and H-5'), 7.95 (1H, 
s, H-8), 8.47 (1H, s, NH-4'), 9.09 (1H, s, NH); 13C NMR 
(125 MHz, DMSO-d6) δ 24.1, 25.2, 25.5, 26.0, 29.2, 36.4, 
36.8, 54.0, 58.2, 70.9, 118.1, 119.2, 119.3, 128.4, 134.3, 
134.9, 138.5, 154.3, 155.3, 155.7, 160.3; LCMS (ES+) m/z 
493.6 [M+H]+; HRMS (ES+) calcd for C26H36N8O2 [M+H]
+ 
493.3034, found 493.3040; λmax (EtOH) 281.5, 238.0 nm.
1-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)
phenyl)-3-(3-(dimethylamino)propyl)urea (18)
Following Method I, the title compound was 
prepared using 6-(cyclohexylmethoxy)-2-fluoro-9H-
purine (9) (0.15 g, 0.59 mmol) and 1-(4-aminophenyl)-
3-(3-(dimethylamino)propyl)urea (see ESI S22; 0.30 
g, 1.17 mmol) and TFA (0.27 mL, 3.5 mmol) in TFE (4 
mL). The compound was purified using the Biotage SP4 
chromatography (KP-NH; MeOH-EtOAc; 1:4) to obtain 
title compound as an off-white solid (94 mg, 34%): mp 
110-112 ºC; IR (cm-1) 2925, 2855, 2127, 2050, 1672 
υ(NN'C=O), 1614, 1551, 1508; 1H NMR (300 MHz, 
DMSO-d6) δ 1.07-1.21 (5H, m, cyclohexyl), 1.50-
1.57 (2H, quin., J = 7.0 Hz, CH2), 1.69-1.75 (6H, m, 
cyclohexyl), 2.12 (6H, s, N(CH3)2), 2.22 (2H, t, J = 7.0 
Hz, CH2), 3.09 (2H, dt, J = 5.5, 7.0 Hz, CH2), 4.30 (2H, d, 
J = 6.0 Hz, OCH2), 6.15 (1H, br t, J = 5.5 Hz, NH), 7.27 
(2H, d, J = 8.5 Hz, H-2' and H-6'), 7.62 (2H, d, J = 8.5 
Hz, H-3' and H-5'), 7.96 (1H, s, H-8), 8.34 (1H, s, NH-4'), 
9.08 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δ 25.2, 
26.0, 27.8, 29.2, 36.8, 37.5, 45.2, 56.8, 70.9, 118.2, 119.2, 
134.3, 134.9, 138.9, 155.5, 155.7, 158.1; LCMS (ES+) m/z 
467.7 [M+H]+; HRMS (ES+) calcd for C24H35N8O2 [M+H]
+ 
467.2877, found 467.2870; λmax (EtOH) 279.0, 238.0 nm.
6-(Cyclohexylmethoxy)-N-(4-nitrophenyl)-9H-purin-2-
amine (19)
The title compound was prepared according to 
Method I using: 6-(cyclohexylmethoxy)-2-fluoro-9H-
purine (9, 2.00 g, 8.0 mmol), 4-nitroaniline (2.21 g, 16.0 
mmol) and TFA (3.06 mL, 40.0 mmol) in TFE (50 mL). 
The crude orange solid was purified by recrystallisation 
from EtOAc and obtained as a yellow solid (2.18 g, 74%): 
mp 180-181 ºC; IR (cm-1) 3390, 3331, 2936, 2862, 2758, 
1728, 1591, 1522 υ(strong, br, NO2 asymmetric stretch), 
1330 υ(strong, sharp, NO2 symmetric stretch); 
1H NMR 
(300 MHz, DMSO-d6) δ 1.02-1.29 (5H, m, cyclohexyl), 
1.66-1.85 (6H, m, cyclohexyl), 4.32 (2H, d, J = 6.0 Hz, 
OCH2), 8.04 (2H, d, J = 9.0, H-2' and H-6'), 8.18 (2H, 
d, J = 9.0, H-3' and H-5'), 8.21 (1H, s, H-8); 13C NMR 
(75 MHz, DMSO-d6) δ 21.0, 25.4, 26.5, 30.1, 71.9, 
117.5, 125.5, 140.2, 148.2, 154.6; LCMS (ES+) m/z 369.3 
[M+H]+; HRMS (ES+) calcd for C18H20N6O3 [M+H]
+ 
369.3614, found 369.3611.
6-(Cyclohexylmethoxy)-N-(3-nitrophenyl)-9H-purin-2-
amine (20)
According to Method I, the title compound was 
prepared using: 6-(cyclohexylmethoxy)-2-fluoro-9H-
purine (9) (2.00 g, 8.0 mmol), 3-nitroaniline (2.21 g, 
16.0 mmol) and TFA (3.06 mL, 40.0 mmol) in TFE (50 
mL). The crude orange solid was purified by column 
chromatography (silica; EtOAc-petrol; 4:6) and isolated 
as a yellow solid (1.89 g, 64%): mp 217-218 ºC; IR (cm-1) 
3419, 3351, 2931, 2854, 2769, 1732, 1592, 1532 υ(strong, 
br, NO2 asymmetric stretch), 1351 υ(strong, sharp, NO2 
symmetric stretch); 1H NMR (300 MHz, DMSO-d6) δ 
1.17 (5H, m, cyclohexyl), 1.77 (6H, m, cyclohexyl), 4.38 
(2H, d, J = 6.0 Hz, OCH2), 7.53 (1H, dd, J = 7.5, 8.0 
Hz, H-5'), 7.73 (1H, dd, J = 1.5, 2.0 Hz, H-2'), 7.94-8.11 
(2H, m, H-4', H-6'), 8.29 (1H, s, H-8), 9.10 (1H, s, N-2 
H); LCMS (ES+) m/z 369.4 [M+H]+; HRMS (ES+) calcd 
for C18H20N6O3 [M+H]
+ 369.3614, found 369.3609; λmax 
(EtOH) 379, 292, 271, 227.5 nm.
Reduction of aryl-nitro groups to corresponding 
anilines (compounds 21 and 22)
To a stirred solution of the nitroaromatic compound 
in sufficient anhydrous solvent as indicated was added 
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10% palladium on activated carbon (30% w/w). The 
resulting mixture was stirred under an atmosphere of H2 
at room temperature for 24 h. The reaction mixture was 
filtered through a bed of Celite eluting with a mixture of 
MeOH-DCM (1:9), to afford the title compound following 
removal of the solvent in vacuo.
2-(4-Aminophenyl)amino-6-cyclohexylmethoxy-purine 
(21)
The title compound was synthesised from 6-(cyclo 
hexylmethoxy)-N-(4-nitrophenyl)-9H-purin-2-amine (19, 
1.20 g, 3.26 mmol) with 10% palladium on activated 
carbon (0.36 g) in THF (100 mL) to obtain the title 
compound as a beige solid (1.10 g, 100%): Rf= 0.30 
(MeOH-DCM; 1:9); mp 228-230 ºC; IR (cm-1) 3431 
υ(NH), 3370 υ(NH2), 3234, 2923, 2834, 2359, 1613, 
1584; 1H NMR (300 MHz, DMSO-d6) δ 1.02-1.29 (5H, 
m, cyclohexyl), 1.69-1.85 (6H, m, cyclohexyl), 4.26 
(2H, d, J = 6.0 Hz, OCH2), 4.72 (2H, br s, NH2), 6.50 
(2H, d, J = 8.5 Hz, H-2' and H-6'), 7.35 (2H, d, J = 8.5 
Hz, H-3' and H-5'), 7.99 (1H, s, H-8), 9.01 (1H, s, NH); 
13C NMR (75 MHz, DMSO-d6) δ 25.2, 26.5, 29.6, 37.2, 
71.1, 113.8, 121.3, 130.2, 143.7, 156.6; LCMS (ES+) m/z 
339.1 [M+H]+; HRMS (ES+) calcd for C18H22N6O [M+H]
+ 
389.1928, found 389.1931; λmax (EtOH) 277.0, 240.0 nm.
2-(3-Aminophenyl)amino-6-cyclohexylmethoxy-purine 
(22)
The title compound was synthesised from 6-(cyclo 
hexylmethoxy)-N-(3-nitrophenyl)-9H-purin-2-amine (20, 
0.30 g, 0.82 mmol) with 10% palladium on activated 
carbon (90 mg) in THF (40 mL) to afford the title 
compound as a brown solid (0.23 g, 84%): mp 117-118 
ºC (dec); IR (cm-1) 3254 υ(NH2), 2922, 2847, 1587, 1443, 
1389, 1352, 1118; 1H NMR (300 MHz, DMSO-d6) δ 1.38-
1.87 (5H, m, cyclohexyl), 1.72 (6H, m, cyclohexyl), 4.31 
(2H, d, J = 6.0 Hz, OCH2), 4.89 (2H, br s, NH2), 6.18 
(1H, dd, J = 7.5, 8.0 Hz, H-5'), 6.95 (3H, m, H-2', H-4', 
H-6'), 7.95 (1H, s, H-8), 8.96 (1H, s, NH); 13C NMR (125 
MHz, DMSO-d6) δ 25.2, 26.0, 29.2, 36.9, 70.9, 104.7, 
107.3, 107.7, 114.5, 128.5, 138.6, 141.5, 148.6, 155.7, 
160.0; LCMS (ES+) m/z 339.0 [M+H]+; HRMS (ES+) 
calcd for C18H22N6O [M+H]
+ 389.1928, found 389.1934; 
λmax (EtOH) 301, 271, 224.5 nm.
Synthesis of aminophenylacetic acid derivatives 
(23 – 25)
To a mixture of the aniline (2.25 mol. equiv.) 
and (9, 1 mol. equiv.) in TFE (5 mL/mmol) was added 
TFA (5 mol. equiv.). The mixture was boiled at reflux 
for 24 h and allowed to cool to room temperature. After 
concentration in vacuo, THF (20 mL) and NaOH aqueous 
solution (1 M, 15 mL) were added to the residue and 
the resulting mixture was stirred overnight. The pH was 
adjusted to around 1 with conc. HCl and the product was 
extracted with EtOAc (250 mL). The organic phase was 
separated, washed with 10 % HCl solution and dried 
(NaSO4). Removal of the solvent gave crude product, 
to which Et2O (100 mL) was added. After allowing the 
mixture to stand for 3 h the resulting precipitate was 
collected by suction filtration and washed with diethyl 
ether (30 mL). Recrystallisation from MeOH gave the 
pure product.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)benzoic 
acid (23)
The title compound was synthesised using 
6-cyclohexylmethoxy-2-fluoro-9-methyl-9H-purine (9, 
250 mg, 1.0 mmol), 3-aminobenzoic acid (309 mg, 2.3 
mmol), TFE (5.0 mL), and TFA (0.37 mL, 5 mmol) 
to give an off-white solid (259 mg, 71%): Rf = 0.18 
(MeOH-EtOAc; 1:9); mp 182-184 °C (dec.); IR (cm-1) 
2925, 2850, 1593, 1564, 1440, 1357, 1114, 972; 1H NMR 
(300 MHz, DMSO-d6) δ 1.0-1.9 (11H, m, cyclohexyl), 
4.36 (2H, d, J = 5.8 Hz, OCH2), 7.35 (1H, dd, J = 7.6, 7.8 
Hz, ArH), 7.49 (1H, d, J = 7.3 Hz, ArH), 7.92 (1H, d, J = 
7.6 Hz, ArH), 8.03 (1H, s, ArH), 8.55 (1H, s, H-8), 9.50 
(1H, s, ArNHAr), 12.86 (1H, s br, N9-H); LCMS (ES+) 
m/z 368 [M+H]+; HRMS (ES+) calcd for C19H22N6O3 
[M+H]+ 368.1717, found 368.1722; λmax (EtOH) 225, 
274 nm.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)phenyl]
acetic acid (24)
The title compound was synthesised using 
6-cyclohexylmethoxy-2-fluoro-9-methyl-9H-purine (9, 
2.0 g, 8.0 mmol), 3-aminophenylacetic acid (2.7 g, 18 
mmol), TFE (20 mL), and TFA (3.0 mL, 40 mmol) to give 
a colourless solid (1.7 g, 55%): Rf = 0.05 (MeOH-EtOAc; 
0.5-9.5); mp 221-222 °C (dec.); IR (cm-1) 3434, 3118, 
2923, 2851, 1603, 1493, 1417, 1261; 1H NMR (300 MHz, 
DMSO-d6) δ 1.0-1.9 (11H, m, cyclohexyl), 3.51 (2H, s, 
ArCH2), 4.33 (2H, d, J = 6.2 Hz, OCH2), 6.79 (1H, d, J 
= 7.3 Hz, ArH), 7.18 (1H, dd, J = 7.8, 7.9 Hz, ArH), 7.65 
(1H, d, J = 8.3 Hz, ArH), 7.73 (1H, s, ArH), 8.00 (1H, 
s, H-8), 9.29 (1H, s, ArNHAr), 12.29 (1H, s br, CO2H), 
12.78 (1H, s br, N9-H); LCMS (ES+) m/z 382 [M+H]+; λmax 
(EtOH) 209, 272 nm.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)phenyl]
propionic acid (25)
The title compound was synthesised using 
6-cyclohexylmethoxy-2-fluoro-9-methyl-9H-purine (9, 
300 mg, 1.2 mmol), 3-(3-aminophenyl)propionic acid 
(446 mg, 2.7 mmol), TFE (5.0 mL), and TFA (0.45 mL, 
6.0 mmol) to give an off-white solid (225 mg, 48%): Rf 
= 0.18 (MeOH-EtOAc; 1:9); mp 231-232 °C (dec.); IR 
(cm-1) 2922, 2849, 1707, 1639, 1595, 1491, 1415, 1251, 
1128, 972; 1H NMR (300 MHz, DMSO-d6) δ 1.0-1.9 
(11H, m, cyclohexyl), 2.53 (2H, t, J = 7.9 Hz, CH2CO2H), 
2.80 (2H, t, J = 7.7 Hz, ArCH2), 4.35 (2H, d, J = 6.3 Hz, 
OCH2), 6.81 (1H, d, J = 7.6 Hz, ArH), 7.17 (1H, dd, J = 
7.8, 7.9 Hz, ArH), 7.58 (1H, d, J = 8.1 Hz, ArH), 7.71 (1H, 
s, ArH), 8.38 (1H, s, H-8), 9.41 (1H, s, ArNHAr), 12.10 
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(1H, s br, N9-H); 13C NMR (125 MHz, DMSO-d6) δ 21.1, 
25.2, 25.9, 29.1, 30.7, 35.3, 36.8, 39.0, 71.4, 116.5, 118.5, 
121.0, 128.3, 139.4, 140.7, 141.0, 154.3, 156.0, 159.0, 
173.7; LCMS (ES+) m/z 396 [M+H]+; HRMS (ES+) calcd 
for C21H26N5O3 [M+H]
+ 396.2030, found 396.2026; λmax 
(EtOH) 272 nm.
2,2,2-Trifluoroethyl-3-(6-cyclohexylmethoxy-9H-purin-
2-ylamino)phenylmethanesulfonate (26)
The title compound was synthesised according to 
Method I using 2-fluoro-6-cyclohexylmethoxypurine 
(9) (1.24 g, 5.0 mmol), 2,2,2-trifluoroethyl 
3-aminophenylmethanesulfonate (S26, 2.8 g, 10 mmol), 
TFE (25 mL), and TFA (1.84 mL, 25 mmol). The crude 
product was adsorbed onto silica (~50 mL) and purified 
by chromatography (silica; EtOAc-petrol; 6:4) to give 
a viscous oil that was triturated with DCM (35 mL), to 
afford a pale yellow powder (1.83 g, 74%): Rf = 0.22 
(EtOAc-petrol; 6:4); mp 199-200 °C; IR (cm-1) 3436, 
3112, 2924, 2848, 1591, 1537, 1494, 1435, 1392, 1338, 
1287, 1151, 1028; 1H NMR (300 MHz, DMSO-d6) δ 1.0-
1.9 (11H, m, cyclohexyl), 4.35 (2H, d, J = 6.2 Hz, OCH2), 
4.84 (2H, s, ArCH2), 4.94 (2H, q, J = 8.6 Hz, CH2CF3), 
6.99 (2H, d, J = 7.6 Hz, 2 × ArH overlap), 7.31 (1H, t, J = 
7.8, 8.1 Hz, ArH), 7.86-7.88 (2H, m, 2 × ArH), 8.03 (1H, 
s, H-8), 9.44 (1H, s, ArNHAr), 12.86 (1H, br, N9-H); 13C 
NMR (125 MHz, DMSO-d6) δ 25.2, 26.0, 29.2, 36.9, 55.5, 
55.7, 64.9 (q, 2JC-F = 36 Hz), 71.2, 114.9, 118.8, 121.5, 
122.6 (q, 1JC-F = 276 Hz), 123.2, 128.6, 139.0, 141.4, 
155.3, 160.1; 19F NMR (470 MHz, DMSO-d6) δ -72.86 
(t, J = 8.6 Hz, CF3); LCMS (ES
+) m/z 500 [M+H]+; Anal. 
calcd for C21H24F3N5O4S: C, 50.50; H, 4.84; N, 14.02%; 
found: C, 50.80; H, 4.56; N, 13.91; λmax (EtOH) 272, 292 
nm.
Synthesis of 4-N-acyl-(2—phenyl)-amino-9H-purines 
(compounds 27-30)
A stirred solution of the 4- (21) or 3-substituted 
aniline (22) (0.20 g, 0.59 mmol), 4-dimethylaminopyridine 
(0.07 g, 0.59 mmol) and Et3N (0.33 mL, 2.36 mmol) in 
THF (5 mL) was maintained at 0 ºC. To the chilled mixture 
was slowly added the required acyl chloride (1.77 mmol) 
and the reaction mixture was allowed to warm to room 
temperature (or heated to reflux as stated) with continued 
stirring for 18 h. EtOAc (20 mL) was added to the crude 
mixture and washed with sat. NaHCO3 solution (3 × 10 
mL). The combined aqueous phase was re-extracted 
using EtOAc (2 × 10 mL). The combined organic extracts 
were washed with 0.1 M HCl (3 × 10 mL) and the acidic 
extracts again re-extracted with EtOAc (2 × 10 mL). The 
combined organic extracts were dried (Na2SO4). Products 
were obtained after purification as described. The N-9 acyl 
compound (0.10 g) was dissolved in a 1:1 mixture of DCM 
(2 mL) and TFA (2 mL) and stirred at room temperature 
for 18 h. After this time, the solvent was removed in vacuo 
and the trifluoroacetate salt of the purine was suspended in 
EtOAc (5 mL). The suspension was washed with saturated 
NaHCO3 solution (3 × 10 mL) and the organic phase was 
dried (Na2SO4). Solvents were removed under reduced 
pressure and the resulting solid was purified as required.
N-(3-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)
phenyl)acetamide (27) 
The title compound was obtained using 
acetyl chloride (0.13 mL, 1.77 mmol) with N-1-
(6-(cyclohexylmethoxy)-9H-purin-2-yl)benzene-
1,3-diamine (22). The crude mixture was purified 
using chromatography (silica; EtOAc) to obtain the 
compound as an off-white solid (0.15 g, 60%): mp 83-
85 ºC; IR (cm-1) 3294, 2923, 2852, 1971, 1734 υ(amide 
C=O), 1671 υ(amide C=O), 1586, 1541; 1H NMR (300 
MHz, DMSO-d6) δ 1.16 (5H, m, cyclohexyl), 1.74 (6H, 
m, cyclohexyl), 2.04 (3H, s, CH3), 2.88 (3H, s, CH3), 4.34 
(2H, d, J = 6.0 Hz, OCH2), 7.02-7.11 (1H, m, H-4'), 7.13-
7.23 (1H, dd, J = 7.5, 8.0 Hz, H-5'), 7.38-7.46 (1H, m, 
H-6'), 8.14-8.15 (1H, m, H-2'), 8.43-8.43 (1H, s, H-8), 
9.65 (1H, s, NH), 9.86 (1H, br s, CONH); 13C NMR (125 
MHz, DMSO-d6) δ 24.0, 25.2, 25.9, 26.0, 29.1, 36.7, 36.8, 
71.0, 71.4, 110.2, 110.5, 112.4, 113.0, 113.9, 114.3, 128.3, 
137.7, 139.3, 156.0, 160.7, 168.0 (C=O), 168.2 (C=O); 
LCMS (ES+) m/z 423.3 [M+H]+; λmax (EtOH) 306.5, 209.0 
nm. After acidolysis according to the general procedure, 
the title compound was isolated as an orange solid was 
achieved without further purification (90 mg, 100%): mp 
93-95ºC; IR (cm-1) 3260, 2923, 2851, 2031, 1666 υ(amide 
C=O), 1591, 1537; 1H NMR (300 MHz, DMSO-d6) δ 1.04-
1.32 (5H, m, cyclohexyl), 1.64-1.84 (6H, m, cyclohexyl), 
2.03 (3H, s, CH3), 4.34 (2H, d, J = 6.0 Hz, OCH2), 7.07-
7.18 (2H, m, H-4' and H-6'), 7.47 (1H, dd, J = 8.0, 8.5 Hz, 
H-5'), 7.96 (1H, m, H-2'), 7.99 (1H, s, H-8), 9.30 (1H, s, 
NH), 9.85 (1H, s, CONH); 13C NMR (125 MHz, DMSO-
d6) δ 18.5, 24.0, 25.2, 26.0, 29.2, 36.8, 56.0, 71.0, 110.2, 
112.4, 113.9, 114.7, 138.8, 139.3, 141.3, 154.2, 155.5, 
160.1, 168.0 (C=O); LCMS (ES+) m/z 381.4 [M+H]+; 
HRMS (ES+) calcd for C20H24N6O2 [M+H]
+ 381.2034, 
found 381.2037; λmax (EtOH) 293.5, 270.0, 230.0 nm.
N-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)
phenyl)pivalamide (28)
The title compound was obtained from 
pivaloyl chloride (0.22 mL, 1.77 mmol) with N-1-(6-
(cyclohexylmethoxy)-9H-purin-2-yl)benzene-1,4-diamine 
(21, 0.20 g, 0.59 mmol), DMAP (70 mg, 0.59 mmol) and 
triethylamine (0.33 mL, 2.36 mmol) at reflux for 18 h. The 
crude mixture was purified using column chromatography 
(silica; EtOAc-petrol; 1:1) to isolate the compound 
as an off-white solid (92 mg, 31%): mp 109-111 ºC; IR 
(cm-1) 3421, 3328, 3123, 2969, 2921, 2844, 1732 υ(amide 
C=O), 1658 υ(amide C=O), 1592, 1561, 1517; 1H NMR 
(300 MHz, DMSO-d6) δ 1.11 (9H, s, 
tBu), 1.16 (5H, m, 
cyclohexyl), 1.50 (9H, s, tBu), 1.71 (6H, m, cyclohexyl), 
4.34 (2H, d, J = 6.0 Hz, OCH2), 7.55 (1H, d, J = 9.0 Hz, 
H-2' and H-6'), 7.67 (1H, d, J = 9.0 Hz, H-3' and H-5'), 
8.43 (1H, s, H-8), 9.11 (1H, s, CONH), 9.51 (1H, s, NH); 
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13C NMR (125 MHz, DMSO-d6) δ 25.9, 26.0, 27.0, 27.1, 
27.3, 28.6, 29.2, 36.6, 37.7, 70.9, 71.4, 118.3, 120.4, 
120.7, 127.5, 128.7, 132.7, 136.7, 137.7, 155.5, 176.0 
(C=O), 176.4 (C=O); LCMS (ES+) m/z 507.5 [M+H]+; 
λmax (EtOH) 312.0; 266.5, 207.5 nm. After acidolysis 
according to the general procedure, the title compound 
was isolated as a pale pink solid and was used without 
further purification (83 mg, 100%): mp 164-166ºC; IR 
(cm-1) 2921, 2850, 2161, 1622 υ(amide C=O), 1589, 
1508; 1H NMR (300 MHz, DMSO-d6) δ 0.92-1.48 (14H, 
m, tBu and cyclohexyl), 1.70-1.84 (6H, m, cyclohexyl), 
4.30.4.34 (2H, d, J = 6.0 Hz, OCH2), 7.50 (2H, d, J = 
7.0 Hz, H-2' and H-6'), 7.60 (2H, d, J = 7.0 Hz, H-3' and 
H-5'), 7.95 (1H, s, H-8), 9.15 (1H, s, NH), 9.22 (1H, s, 
CONH); LCMS (ES+) m/z 423.5 [M+H]+; HRMS (ES+) 
calcd for C23H30N6O [M+H]
+ 423.2503, found 423.2509; 
λmax (EtOH) 369.5, 300.0, 291.5, 284.0, 207.0 nm.
N-(4-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)
phenyl)benzamide (29)
The title compound was obtained from 
benzoyl chloride (0.21 mL, 1.77 mmol) with N-1-(6-
(cyclohexylmethoxy)-9H-purin-2-yl)benzene-1,4-diamine 
(21, 0.20 g, 0.59 mmol), DMAP (70 mg, 0.59 mmol) and 
triethylamine (0.33 mL, 2.36 mmol). The crude mixture 
was purified using chromatography (silica; EtOAc-
petrol; 1:4) to obtain the compound as a white solid (0.26 
g, 81%): mp 206-208 ºC; IR (cm-1) 3301, 3139, 2920, 
2845, 1701 υ(amide C=O), 1634 υ(amide C=O), 1549, 
1506; 1H NMR (300 MHz, DMSO-d6) δ 1.00-1.39 (5H, 
s, cyclohexyl), 1.60-1.95 (6H, s, cyclohexyl), 4.35 (2H, 
d, J = 6.0 Hz, OCH2), 7.19-7.29 (2H, d, J = 8.0 Hz, 
H-2' and H-6'), 7.38-7.46 (2H, d, J = 8.0 Hz, H-3' and 
H-5'), 7.49-7.69 (5H, m, Ph), 7.80-7.88 (1H, t, J = 7.5, 
Hz, Ph), 7.89-7.99 (4H, m, Ph), 8.43 (1H, s, H-8), 9.52 
(1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δ 25.2, 26.0, 
29.2, 36.8, 71.3, 115.4, 118.0, 120.5, 127.5, 128.3, 128.6, 
130.3, 131.3, 132.0, 132.7, 132.9, 135.2, 136.2, 139.2, 
152.7, 155.6, 160.6, 165.1 (C=O), 166.5 (C=O); LCMS 
(ES+) m/z 546.3 [M+H]+; λmax (EtOH) 315.0, 229.5 nm. 
After acidolysis according to the general procedure, the 
title compound was isolated as a beige solid was isolated 
and was used without further purification (81 mg, 100%): 
mp 260-262ºC; IR (cm-1) 3300, 3139, 2920, 2845, 1634 
υ(amide C=O), 1553, 1506; 1H NMR (300 MHz, DMSO-
d6) δ 0.99-1.37 (5H, m, cyclohexyl), 1.58-1.96 (6H, m, 
cyclohexyl), 4.27-4.40 (2H, d, J = 6.0 Hz, OCH2), 7.48-
7.60 (3H, m, phenyl), 7.62-7.72 (2H, d, J = 9.0 Hz, H-2' 
and H-6'), 7.73-7.83 (2H, d, J = 9.0 Hz, H-3' and H-5'), 
7.91-8.05 (3H, m, phenyl and H-8), 9.28 (1H, s, NH), 
10.14 (1H, s, CONH), 12.68-12.93 (1H, br s, N9-H); 13C 
NMR (125 MHz, DMSO-d6) δ 25.2, 26.0, 29.2, 36.8, 71.0, 
118.5, 120.8, 127.5, 128.3, 131.3, 132.5, 135.1, 137.1, 
155.5, 165.0 (C=O); LCMS (ES+) m/z 443.5 [M+H]+; 
HRMS (ES+) calcd for C25H26N6O2 [M+H]
+ 443.2190, 
found 443.2196; λmax (EtOH) 315.0 nm.
N-[4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]isonicotinamide (30)
The title compound was obtained from 
isonicotinoyl chloride (0.32 g, 1.77 mmol) with N-1-(6-
(cyclohexylmethoxy)-9H-purin-2-yl)benzene-1,4-diamine 
(21, 0.2 g, 1.77 mmol), DMAP (70 mg, 0.59 mmol) and 
triethylamine (0.33 mL, 2.36 mmol). The crude mixture 
was washed with saturated NaHCO3 solution (20 mL) 
and beige solid collected by filtration and washed with 
MeOH (20 mL) (0.14 g, 43%): mp 248-250 ºC (dec.); IR 
(cm-1) 3339, 2927, 2851, 1664 υ(amide C=O), 1622, 1587, 
1544, 1516; 1H NMR (300 MHz, DMSO-d6) δ 1.30-1.07 
(5H, m, cyclohexyl), 1.83-1.71 (6 H, m, cyclohexyl), 4.32 
(2H, d, J = 6.0 Hz, OCH2), 7.83 (2H, d, J = 8.5 Hz, H-2' 
and H-6'), 7.87 (2H, d, J = 5.5 Hz, pyridyl), 7.64 (2H, 
d, J = 8.5 Hz, H-3' and H-5'), 8.78 (2H, d, J = 5.5 Hz, 
pyridyl), 9.05 (1H, s, NH), 10.46-10.33 (1H, s, CONH); 
13C NMR (125 MHz, DMSO-d6) δ 25.2, 26.0, 29.3, 36.9, 
70.8, 118.1, 120.9, 121.5, 131.4, 138.1, 142.1, 150.2, 
154.7, 157.4 (C=O), 159.3 (C=O), 163.3; LCMS (ES+) 
m/z 444.4 [M+H]+; HRMS (ES+) calcd for C24H25N7O 
444.2142 [M+H]+, found 444.2143; λmax(EtOH) 315.5, 
271.0, 206.0 nm.
Synthesis of urea-substituted 2-arylaminopurines (e.g. 
31 – see ESI for further example)
To a stirred suspension of the required N-(6-cyclo 
hexylmethoxy-9H-purin-2-yl)benzene-diamine (21 or 22) 
(0.20 g, 0.59 mmol) and NaOCN (80 mg, 1.18 mmol) in 
a mixture of DCM (10 mL) and DMF (3 mL) was added 
TFA (9 μL, 1.18 mmol) over 2 min. The mixture was 
stirred under N2 for 18 h. Solvents were removed under 
reduced pressure and the residue was dissolved in DCM 
(25 ml) and extracted with 0.1 M HCl (3 × 20 mL). The 
organic extract was dried using (Na2SO4) and the filtrate 
was concentrated to give a beige solid as crude mixture of 
mono- and di-urea compounds. The mixture was dissolved 
in a 1:1 mixture of DCM (2 mL) and TFA (2 mL) and 
stirred at room temperature for 18 h. After this time, the 
solvent was removed and the trifluoroacetate salt of the 
purine was suspended in EtOAc (5 mL). The suspension 
was washed with saturated NaHCO3 solution (3 × 10 mL) 
and the organic phase was dried (Na2SO4). Solvents were 
removed under reduced pressure and the resulting solid 
was used without further purification.
1-(3-(6-(Cyclohexylmethoxy)-9H-purin-2-ylamino)
phenyl) urea (31)
Using N-(6-cyclohexylmethoxy-9H-purin-2-yl)
benzene-1,3-diamine (22) the product was obtained as a 
off-white solid (0.14 g, 64%) was isolated without further 
purification: mp193-194 ºC; IR (cm-1) 3285 υ(NH2), 3159, 
2919, 2849, 1674 υ(NN'C=O), 1620, 1589, 1541; 1H NMR 
(300 MHz, DMSO-d6) δ 1.17 (5H, m, cyclohexyl), 1.74 
(6H, m, cyclohexyl), 4.33 (2H, d, J = 6.0 Hz, OCH2), 
7.05 (2H, m, H-4' and H-6'), 7.43 (1H, dd, J = 7.5, 8.0 
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Hz, H-5'), 7.67 (1H, s, H-2'), 7.95 (1H, s, H-8), 8.46 
(1H, s, NH-4'), 9.21 (1H, s, NH), 12.77 (1H, s, NH-9); 
13C NMR (75 MHz, DMSO-d6) δ 14.4, 25.6, 26.4, 29.6, 
37.3, 71.4, 109.7, 128.5, 138.9, 140.9, 141.7, 156.1, 156.3; 
LCMS (ES+) m/z 382.3 [M+H]+; HRMS (ES+) calcd for 
C19H23N7O2 [M+H]
+ 382.4311, found 382.4312; λmax 
(EtOH) 295.0, 272.0, 229.0 nm.
Synthesis of amide derivatives (compounds 32-47)
To the appropriate carboxylic acid (23-24) (1 
mol. equiv.) and DIPEA (2 mol. equiv.) in DMF (3 mL/
mmol) was added carbonyldiimidazole (2 mol. equiv.) 
and the resulting mixture was stirred for 1.5 h at room 
temperature. The appropriate amine (4 mol. equiv.) 
was added and the reaction was stirred overnight. 
Solvents were removed and the residue was extracted 
into EtOAc or THF depending on solubility. The extract 
was washed with saturated aqueous NaHCO3 and dried 
(Na2SO4). The solvent was removed to afford the crude 
product, which was purified as indicated by either by 
chromatography on silica, or by using the Biotage SP4 
purification system.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)phenyl]
piperidin-1-ylmethanone (32)
The title compound was prepared using 23 (50 mg, 
0.14 mmol), carbonyldiimidazole (45 mg, 0.28 mmol), 
DIPEA (50 μL, 0.28 mmol), and piperidine (55 μL, 0.56 
mmol) in DMF (2 mL). The crude product was purified 
by chromatography on silica using EtOAc-petrol (9:1) as 
eluent to give an off-white powder (33 mg, 54%): Rf = 0.48 
(EtOAc); mp 133-135 °C; IR (cm-1) 2923, 2850, 1581, 
1539, 1437, 1390, 1348, 1276, 1209, 1114, 975; 1H NMR 
(300 MHz, DMSO-d6) δ 1.1-1.9 (17H, m, cyclohexyl and 
piperidyl), 3.34 (br, overlap with H2O, NCH2), 3.58 (2H, 
s, NCH2), 4.34 (2H, d, J = 6.3 Hz, OCH2), 6.87 (1H, d, 
J = 7.5 Hz, ArH), 7.31 (1H, dd, J = 7.8, 7.9 Hz, ArH), 
7.79 (1H, d, J = 8.3 Hz, ArH), 7.94 (1H, s, ArH), 8.03 
(1H, s, H-8), 9.46 (1H, s, ArNHAr), 12.87 (1H, s br, N9-
H); LCMS (ES+) m/z 435.42 [M+H]+; Anal. calcd for 
C24H30N6O2: C, 66.34; H, 6.96; N, 19.34%; found: C, 
66.41; H, 7.07; N, 19.04; λmax (EtOH) 273, 293 nm.
3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N-(4-
dimethylaminobutyl)benzamide (33)
The title compound was prepared using 23 (80 
mg, 0.22 mmol), carbonyldiimidazole (71 mg, 0.44 
mmol), DIPEA (79 μL, 0.44 mmol), and N,N-dimethyl-
1,4-butanediamine (128 mg, 1.1 mmol) in DMF (3 mL). 
The crude product was purified using a Biotage SP4 
purification system (12 + M KP-NH Si cartridge; MeOH-
EtOAc; 1:4) to give a colourless powder (53 mg, 51%): 
Rf = 0.67 (NH2-modified silica – MeOH-EtOAc; 1:4); 
mp 125-127 °C; IR (cm-1) 3076, 2920, 2849, 2363, 2337, 
1597, 1537, 1483, 1438, 1391, 1352, 1283, 1117, 973; 
1H NMR (300 MHz, DMSO-d6) δ 1.00-1.90 (15H, m, 
cyclohexyl and CH2CH2CH2CH2), 2.11 (6H, s, 2 × CH3), 
2.21 (2H, t, J = 6.9 Hz, Me2NCH2), 3.25 (2H overlap with 
H2O, m, CH2CH2NHCO), 4.35 (2H, d, J = 6.1 Hz, OCH2), 
7.29-7.34 (2H, m, 2 × ArH), 7.85 (1H, m, ArH), 8.01 (1H, 
s, H-8), 8.31 (1H, s, ArH), 8.38 (1H, t, J = 5.3 Hz, CONH), 
9.40 (1H, s, ArNHAr); LCMS (ES+) m/z 466.50 [M+H]+; 
HRMS (ES+) calcd for C25H36N7O2 [M+H]
+ 466.2925, 
found 466.2920; λmax (EtOH) 273, 293 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-anilino)]-N-
isobutylacetamide (34)
The title compound was prepared using 24 (60 mg, 
0.16 mmol), carbonyldiimidazole (50 mg, 0.31 mmol), 
DIPEA (56 μL, 0.31 mmol), and isobutylamine (64 μL, 
0.63 mmol) in DMF (2 mL). The crude product was 
purified by chromatography (silica; EtOAc-petrol; 9:1) to 
give a white powder (35 mg, 52%): Rf = 0.59 (EtOAc); 
mp 144-145 °C; IR (cm-1) 3280, 3091, 2925, 2853, 1643, 
1586, 1437, 1344, 1256, 1161, 974; 1H NMR (300 MHz, 
DMSO-d6) δ 0.82 (6H, d, J = 6.7 Hz, CH(CH3)2), 1.0–2.0 
(11H, m, cyclohexyl), 1.69 (1H, m, CH2CH(CH3)2), 2.88 
(2H, t, J = 6.5 Hz, CH2NHCO), 3.37 (2H, s, ArCH2), 4.34 
(2H, d, J = 6.3 Hz, OCH2), 6.82 (1H, d, J = 7.6 Hz, ArH), 
7.17 (1H, dd, J = 7.8, 7.9 Hz, ArH), 7.64 (1H, s, ArH), 
7.71 (1H, d, J = 8.2 Hz, ArH), 7.97 (1H, t, J = 5.6 Hz, 
CONH), 8.15 (1H, s, H-8), 9.26 (1H, s, ArNHAr), 12.76 
(1H, br, N9-H); LCMS (ES+) m/z 437 [M+H]+; HRMS 
(ES+) calcd for C24H33N6O2 [M+H]
+ 437.2660, found 
437.2659; λmax (EtOH) 214, 272, 291 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylanilino]-N-
cyclopentylacetamide (35)
The title compound was prepared using 24 (60 mg, 
0.16 mmol), carbonyldiimidazole (50 mg, 0.31 mmol), 
DIPEA (56 μL, 0.31 mmol), and cyclopentylamine (62 
μL, 0.63 mmol) in DMF (2 mL). The crude product was 
purified by chromatography (silica; EtOAc-petrol; 9:1) to 
give a white powder (14 mg, 20%): Rf = 0.57 (EtOAc); 
mp 228-229 °C; IR (cm-1) 3277, 2925, 2851, 1641, 1587, 
1537, 1441, 1394, 1251; 1H NMR (300 MHz, DMSO-d6) 
δ 1.0–1.9 (19H, m, cyclohexyl and cyclopentyl), 3.17 (2H, 
s, ArCH2), 3.97 (1H, m, cyclopentyl), 4.34 (2H, d, J = 6.7 
Hz, OCH2), 6.80 (1H, d, J = 7.3 Hz, ArH), 7.18 (1H, dd, 
J = 7.4, 7.6 Hz, ArH), 7.60 (1H, s, ArH), 7.71 (1H, d, J 
= 7.7 Hz, ArH), 8.01 (1H, d, J = 7.6 Hz, CONH), 9.27 
(1H, s, ArNHAr), 12.79 (1H, br, N9-H); LCMS (ES+) m/z 
449 [M+H]+; HRMS (ES+) calcd for C25H33N6O2 [M+H]
+ 
449.2660, found 449.2664; λmax (EtOH) 216, 272 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylanilino]-N-
cyclohexylacetamide (36)
The title compound was prepared using 24 (60 mg, 
0.16 mmol), carbonyldiimidazole (50 mg, 0.31 mmol), 
DIPEA (56 μL, 0.31 mmol), and cyclohexylamine (72 
μL, 0.63 mmol) in DMF (2 mL). The crude product was 
purified by chromatography (silica; EtOAc-petrol; 9:1) to 
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give a white powder (17 mg, 24%): Rf = 0.64 (EtOAc); 
mp 226-227 °C; IR (cm-1) 3272, 2922, 2850, 2159, 1639, 
1585, 1537, 1442, 1346, 1253, 1126; 1H NMR (300 MHz, 
DMSO-d6) δ 1.0–1.9 (21H, m, cyclohexyl), 3.35 (2H, s, 
ArCH2 overlap with H2O), 3.50 (1H, m, cyclohexyl 3′ 
CH), 4.34 (2H, d, J = 6.2 Hz, OCH2), 6.81 (1H, d, J = 7.4 
Hz, ArH), 7.17 (1H, dd, J = 7.6, 8.1 Hz, ArH), 7.59 (1H, s, 
ArH), 7.71 (1H, d, J = 8.5 ArH), 7.89 (1H, d, J = 7.7 Hz, 
CONH), 7.96 (1H, s, H-8), 9.26 (1H, s, ArNHAr), 12.76 
(1H, br, N9-H); LCMS (ES+) m/z 463 [M+H]+; HRMS 
(ES+) calcd for C26H35N6O2 [M+H]
+ 463.2816, found 
463.2815; λmax (EtOH) 215, 272 nm.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylanilino]-N-
methyl-N-cyclohexylacetamide (37)
The title compound was prepared using 24 
(50 mg, 0.13 mmol), carbonyldiimidazole (42 mg, 
0.26 mmol), DIPEA (43 μL, 0.26 mmol), and N-
methylcyclohexylamine (69 μL, 0.52 mmol) in DMF (2 
mL). The crude product was purified by chromatography 
(silica; EtOAc-petrol; 9:1) to give a white powder (14 
mg, 23%): Rf = 0.67 (EtOAc); mp 134-135 °C; IR (cm
-1) 
2922, 2850, 2157, 1583, 1539, 1489, 1437, 1390, 1205, 
1123; 1H NMR (300 MHz, DMSO-d6) δ 1.0–1.9 (21H, 
m, cyclohexyl), 2.72 (3H, s, NCH3), 3.65 (2H, s, ArCH2), 
4.27 (1H, m, cyclohexyl 3′ CH), 4.33 (2H, d, J = 5.9 Hz, 
OCH2), 6.76 (1H, d, J = 7.8 Hz, ArH), 7.18 (1H, dd, J 
= 7.8, 8.0 Hz, ArH), 7.62 (1H, s, ArH), 7.67-7.72 (2H, 
m, ArH and H-8), 9.27 (1H, s, ArNHAr), 12.79 (1H, br, 
N9-H); LCMS (ES+) m/z 477 [M+H]+; HRMS (ES+) calcd 
for C18H22N5O2 [M+H]
+ 477.2973, found 477.2972; λmax 
(EtOH) 216, 272, 291 nm.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylanilino]-N, N-
diisopropylacetamide (38)
The title compound was prepared using 24 (60 mg, 
0.16 mmol), carbonyldiimidazole (50 mg, 0.31 mmol), 
DIPEA (56 μL, 0.31 mmol), and diisopropylamine (89 
μL, 0.63 mmol) in DMF (2 mL). The crude product was 
purified by chromatography (silica; EtOAc-petrol; 9:1) to 
give a white powder (35 mg, 49%): Rf = 0.71 (EtOAc); 
mp 126-127 °C; IR (cm-1) 2925, 2851, 2160, 1586, 1441, 
1342, 1211, 1118; 1H NMR (300 MHz, DMSO-d6) δ 
1.0–1.9 (11H, m, cyclohexyl), 1.05 (6H, d, J = 6.5 Hz, 
CH(CH3)2), 1.40 (6H, d, J = 6.7 Hz, CH(CH3)2), 3.41 (1H, 
m, 3′ i-propyl CH), 3.66 (2H, s, ArCH2), 4.00 (1H, m, 3′ 
i-propyl CH), 4.30 (2H, d, J = 6.2 Hz, OCH2), 6.82 (1H, d, 
J = 7.8 Hz, ArH), 7.18 (1H, dd, J = 7.9, 8.3 Hz, ArH), 7.47 
(1H, m, ArH), 7.59 (1H, s, ArH), 7.64 (1H, s, H-8), 11.65 
(1H, br, N9-H); LCMS (ES+) m/z 465 [M+H]+; HRMS 
(ES+) calcd for C26H37N6O2 [M+H]
+ 465.2973, found 
465.2976; λmax (EtOH) 214, 272, 292 nm.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylanilino]-N-
propylacetamide (39)
The title compound was prepared using 24 (50 
mg, 0.13 mmol), carbonyldiimidazole (42 mg, 0.26 
mmol), DIPEA (43 μL, 0.26 mmol), and n-propylamine 
(42 μL, 0.52 mmol) in DMF (2 mL). The crude product 
was purified by chromatography (silica; MeOH-EtOAc; 
0.5:9.5) to give a white powder (13 mg, 24%): Rf = 0.23 
(MeOH-EtOAc; 0.5:9.5); mp 141-142 °C (dec.); IR (cm-1) 
3275, 3081, 2929, 2853, 1648, 1450, 1358, 1256; 1H NMR 
(300 MHz, DMSO-d6) δ 0.81 (3H, t, J = 7.8 Hz, CH2CH3), 
1.0–1.81 (13H, m, cyclohexyl and CH3CH2), 2.99 (2H, m, 
CH2CH2NH), 3.49 (2H, s, ArCH2), 4.32 (2H, d, J = 6.2 
Hz, OCH2), 6.79 (1H, d, J = 7.3 Hz, ArH), 7.16 (1H, dd, 
J = 7.6, 7.8 Hz, ArH), 7.62 (1H, s, ArH), 7.97 (1H, d, J = 
8.26 Hz, ArH), 7.97 (2H, br, CONH and H-8), 9.24 (1H, 
s, ArNHAr), 12.81 (1H, s br, N9-H); LCMS (ES+) m/z 423 
[M+H]+; λmax (EtOH) 272 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino]-N-(3-
hydroxy-propyl)phenylacetamide (40)
The title compound was prepared using 24 (60 mg, 
0.16 mmol), carbonyldiimidazole (50 mg, 0.31 mmol), 
DIPEA (56 μL, 0.31 mmol), and 3-amino-1-propanol 
(48 μL, 0.63 mmol) in DMF (2 mL). The crude product 
was purified by chromatography (silica; MeOH-EtOAc; 
0.5:9.5) to give a white powder (24 mg, 34%): Rf = 0.08 
(EtOAc); mp 132-133 °C; IR (cm-1) 3267, 2920, 2845, 
1641, 1587, 1494, 1436, 1256; 1H NMR (300 MHz, 
DMSO-d6) δ 1.0–1.9 (11H, m, cyclohexyl), 1.55 (2H, m, 
CH2CH2CH2), 3.11 (2H, m, CH2NH), 3.36-3.42 (4H, m, 
ArCH2, CH2OH), 4.34 (2H, d, J = 6.5 Hz, OCH2), 6.81 
(1H, d, J = 7.3 Hz, ArH), 7.18 (1H, dd, J = 7.7, 8.3 Hz, 
ArH), 7.63 (1H, s, ArH), 7.71 (1H, d, J = 8.9 Hz, ArH), 
8.01 (2H, br m, H-8 and CONH), 9.27 (1H, s, ArNHAr), 
12.89 (1H, br, N9-H); LCMS (ES+) m/z 439 [M+H]+; 
HRMS (ES+) calcd for C23H31N6O3 [M+H]
+ 439.2452, 
found 439.2451; λmax (EtOH) 272, 291 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(3-imidazol-1-yl-propyl)acetamide (41)
The title compound was prepared using 24 (50 mg, 
0.13 mmol), carbonyldiimidazole (42 mg, 0.26 mmol), 
DIPEA (43 μL, 0.26 mmol), and N-(3-aminopropyl)
imidazole (62 μL, 0.52 mmol) in DMF (2 mL). The crude 
product was purified using a Biotage SP4 purification 
system (12 + M KP-NH silica cartridge; MeOH-EtOAc; 
1.5:8.5) to give a white powder (15 mg, 24%): Rf = 
0.03 (MeOH-EtOAc; 1:4); mp 192-193 °C; IR (cm-1) 
3272, 3199, 2923, 2843, 1616, 1548, 1434, 1381, 1349, 
1220, 1122; 1H NMR (300 MHz, DMSO-d6) δ 1.0–1.9 
(13H, m, cyclohexyl and CH2CH2CH2), 3.02 (2H, m, 
CH2NH), 3.40 (2H, s, ArCH2CONH), 3.92 (2H, t, J = 
6.9, CH2), 4.32 (2H, d, J = 6.5 Hz, OCH2), 6.81 (1H, d, 
J = 7.6 Hz, ArH), 6.85 (1H, s, imidazole-H), 7.13 (1H, s, 
imidazole-H), 7.17 (1H, dd, J = 7.8, 8.0 Hz, ArH), 7.57 
(1H, s, imidazole-H), 7.63 (1H, s. ArH), 7.71 (1H, d, J 
= 7.8 Hz, ArH), 8.1 (1H, s, H-8), 9.27 (1H, s, ArNHAr); 
LCMS (ES+) m/z 489 [M+H]+; HRMS (ES+) calcd for 
C26H33N8O2 [M+H]
+ 489.2721, found 489.2724; λmax 
(EtOH) 215, 273, 292 nm.
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2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(3-dimethylamino-propyl)acetamide (42)
The title compound was prepared using 24 (50 mg, 
0.13 mmol), carbonyldiimidazole (42 mg, 0.26 mmol), 
DIPEA (43 μL, 0.26 mmol), and N,N-dimethyl-1,3-
propanediamine (67 μL, 0.52 mmol) in DMF (2 mL). 
The crude product was purified using a Biotage SP4 
purification system (12 + M KP-NH silica cartridge; 
MeOH-EtOAc; 1.5:8.5) to give a white powder (15 mg, 
24%): Rf = 0.03 (MeOH-EtOAc; 1:4); mp 96-97 °C; IR 
(cm-1) 2924, 2850, 2157, 1587, 1537, 1442, 1352, 1249, 
1119; 1H NMR (300 MHz, DMSO-d6) δ 1.03 (2H, d, J 
= 6.6 Hz, CH2CH2CH2), 1.0–1.9 (11H, m, cyclohexyl), 
2.11 (6H, s, N(CH3)2), 2.19 (2H, m, CH2N(CH3)2), 3.25-
3.40 (overlap with H2O, CH2NH and ArCH2), 4.34 (2H, 
d, J = 6.3 Hz, OCH2), 6.80 (1H, d, J = 7.6 Hz, ArH), 
7.16 (1H, dd, J = 7.8, 7.9 Hz, ArH), 7.63 (1H, s, ArH), 
7.70 (1H, br, CONH), 7.81 (1H, d, J = 7.9 Hz, ArH), 
7.95 (1H, s, H-8), 9.17 (1H, s, ArNHAr); LCMS (ES+) 
m/z 466 [M+H]+; HRMS (ES+) calcd for C25H36N7O2 
[M+H]+ 466.2925, found 466.2929; λmax (EtOH) 215, 
272, 292 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(2-dimethylaminoethyl)acetamide (43)
The title compound was prepared using 24 
(75 mg, 0.20 mmol), carbonyldiimidazole (65 mg, 
0.40 mmol), DIPEA (72 μL, 0.40 mmol), and N,N-
dimethylethylenediamine (71 mg, 0.80 mmol) in DMF 
(3 mL). The crude product was purified using a Biotage 
SP4 purification system (12 + M KP-NH silica cartridge; 
MeOH-EtOAc; 1:9) to give a colourless powder (56 mg, 
62%): Rf = 0.10 (NH2-modified silica; MeOH-EtOAc; 
1:9); mp 161-162 °C; IR (cm-1) 3249, 2918, 2845, 1587, 
1541, 1438, 1396, 1346, 1292, 1240, 1116; 1H NMR (300 
MHz, DMSO-d6) δ 1.0–1.84 (11H, m, cyclohexyl), 2.12 
(6H, s, N(CH3)2), 2.27 (2H, t, J = 6.7 Hz, CH2N(Me)2), 
3.13 (2H, m, CH2NHCO), 3.34 (ArCH2, overlap with 
H2O), 4.33 (2H, d, J = 6.2 Hz, OCH2), 6.81 (1H, d, J = 
7.4 Hz, ArH), 7.17 (1H, t, J = 7.8, 7.8 Hz, ArH), 7.64 
(1H, s, ArH), 7.69 (1H, d, J = 8.0 Hz, ArH), 7.93 (1H, 
br t, J = 5.2 Hz, CONH), 7.98 (1H, s, H-8), 9.27 (1H, 
s, ArNHAr), 12.80 (1H, s, N9-H); 13C NMR (125 MHz, 
DMSO-d6) δ 25.2, 26.0, 29.2, 36.9, 42.6, 45.2, 58.2, 71.0, 
116.6, 119.3, 121.4, 128.1, 136.5, 138.8, 141.0, 155.5, 
170.0; LCMS (ES+) m/z 452.65 [M+H]+; HRMS (ES+) 
calcd for C24H34N7O2 [M+H]
+ 452.2768, found 452.2766; 
λmax (EtOH) 272 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(3-methylbutyl)acetamide (44)
The title compound was prepared using 24 (60 
mg, 0.16 mmol), carbonyldiimidazole (52 mg, 0.32 
mmol), DIPEA (57 μL, 0.32 mmol), and isopentylamine 
(74 μL, 0.64 mmol) in DMF (3 mL). The crude product 
was purified by chromatography (silica; MeOH-EtOAc; 
0.5:9.5) to give an off-white solid (34 mg, 48%): Rf = 
0.45 (MeOH-EtOAc; 1:9); mp 204-205 °C; IR (cm-1) 
3326, 3232, 3137, 3061, 2920, 2851, 2162, 2023, 1643, 
1593, 1530, 1487, 1440, 1390, 1354, 1282, 1240, 1170, 
1127; 1H NMR (300 MHz, DMSO-d6) δ 0.84 (6H, d, J = 
6.6 Hz, (CH3)2CH), 1.0–1.85 (11H, m, cyclohexyl), 1.28 
(2H, m, CHCH2CH2), 1.56 (1H, m, (CH3)2CHCH2), 3.05 
(2H, m, CH2CH2NH), 3.35 (ArCH2, overlap with H2O), 
4.33 (2H, d, J = 6.2 Hz, OCH2), 6.80 (1H, d, J = 7.6 Hz, 
ArH), 7.17 (1H, dd, J = 7.8, 7.8 Hz, ArH), 7.63 (1H, s, 
ArH), 7.68 (1H, d, J = 8.1 Hz, ArH), 7.95 (1H, br t, J = 
5.3 Hz, CONH), 8.00 (1H, s, H-8), 9.26 (1H, s, ArNHAr), 
12.83 (1H, s, N9-H); LCMS (ES+) m/z 451 [M+H]+; 
HRMS (ES+) calcd for C25H35N6O2 [M+H]
+ 451.2816, 
found 451.2820; Anal. calcd for C25H34N6O2: C, 66.64; H, 
7.61; N, 18.66%; found: C, 66.44; H, 7.68; N, 18.60; λmax 
(EtOH) 267 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(4-dimethylaminobutyl)acetamide (45)
The title compound was prepared using 24 (75 
mg, 0.20 mmol), carbonyldiimidazole (65 mg, 0.40 
mmol), DIPEA (72 μL, 0.40 mmol), and N,N-dimethyl-
1,4-butanediamine (93 mg, 0.80 mmol) in DMF (3 mL). 
The crude product was purified using a Biotage SP4 
purification system (12 + M KP-NH silica cartridge; 
MeOH-EtOAc; 1.5:8.5) to give a colourless powder (61 
mg, 64%): Rf = 0.12 (NH2-modified silica; MeOH-EtOAc: 
1:9); mp 125-127 °C; IR (cm-1) 3490, 3276, 3052, 2927, 
2852, 2779, 1606, 1558, 1495, 1448, 1400, 1354, 1309, 
1246, 1217; 1H NMR (300 MHz, DMSO-d6) δ 1.0–1.84 
(15H, m, cyclohexyl and CH2CH2CH2CH2), 2.14 (2H, t, 
J = 5.7 Hz, CH2N(Me)2), 3.04 (2H, m, CH2NHCO), 3.34 
(ArCH2, overlap with H2O), 4.33 (2H, d, J = 5.8 Hz, 
OCH2), 6.81 (1H, d, J = 7.4 Hz, ArH), 7.17 (1H, dd, J 
= 7.8, 7.9 Hz, ArH), 7.64 (1H, s, ArH), 7.69 (1H, d, J = 
8.0 Hz, ArH), 8.00 (2H, br, CONH and H-8), 9.27 (1H, 
s, ArNHAr), 12.82 (1H, s, N9-H); 13C NMR (125 MHz, 
DMSO-d6) δ 24.4, 25.2, 26.0, 27.0, 29.2, 36.8, 38.5, 42.8, 
45.1, 58.7, 71.0, 116.5, 119.2, 121.3, 128.1, 136.6, 141.0, 
155.4, 169.8; LCMS (ES+) m/z 480.71 [M+H]+; HRMS 
(ES+) calcd for C26H38N7O2 [M+H]
+ 480.3081, found 
480.3084; λmax (EtOH) 272 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-[3-(4-methylpiperazin-1- yl)propyl]
acetamide (46)
The title compound was prepared using 24 (75 mg, 
0.20 mmol), carbonyldiimidazole (65 mg, 0.40 mmol), 
DIPEA (72 μL, 0.40 mmol), and 1-(3-aminopropyl)-4-
methylpiperazine (126 mg, 0.80 mmol) in DMF (3 mL). 
The crude product was purified using a Biotage SP4 
purification system (12 + M KP-NH silica cartridge; 
MeOH-EtOAc; 1:4) to give a colourless powder (72 mg, 
69%): Rf = 0.09 (NH2-modified silica; MeOH-EtOAc; 1:9); 
mp 157-158 °C; IR (cm-1) 3614, 3273, 3203, 3108, 3039, 
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2923, 2848, 2802, 1639, 1606, 1585, 1495, 1451, 1394, 
1354, 1131, 1216, 1127; 1H NMR (300 MHz, DMSO-d6) δ 
1.0–1.85 (13H, m, cyclohexyl and NCH2CH2CH2N), 2.11 
(3H, s, NCH3), 2.22 (8H, br t, J = 7.2 Hz, 2 × NCH2CH2N), 
3.05 (2H, m, CH2CH2NHCO), 3.34 (ArCH2, overlap with 
H2O), 4.33 (2H, d, J = 6.1 Hz, OCH2), 6.80 (1H, d, J = 7.5 
Hz, ArH), 7.17 (1H, dd, J = 7.8, 7.8 Hz, ArH), 7.64 (1H, s, 
ArH), 7.68 (1H, d, J = 8.0 Hz, ArH), 7.97 (2H, br, CONH 
and H-8), 9.28 (1H, s, ArNHAr), 12.79 (1H, s, N9-H); 
13C NMR (125 MHz, DMSO-d6) δ 25.2, 26.0, 26.3, 29.2, 
36.8, 37.1, 42.8, 45.7, 52.6, 54.7, 55.4, 71.0, 116.6, 119.2, 
121.4, 128.1, 136.5, 141.0, 155.4, 169.9; HRMS (ES+) 
calcd for C28H41N8O2 [M+H]
+ 521.3347, found 521.3352; 
λmax (EtOH) 272 nm.
2-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(3-phenylpropyl)acetamide (47)
The title compound was prepared using 24 (75 mg, 
0.20 mmol), carbonyldiimidazole (65 mg, 0.40 mmol), 
DIPEA (72 μL, 0.40 mmol), and 3-phenylpropylamine 
(108 mg, 0.80 mmol) in DMF (3 mL). The crude product 
was purified by chromatography (silica; EtOAc) to give an 
off-white solid (53 mg, 53%): Rf = 0.46 (MeOH-EtOAc; 
1:9); mp 154-155 °C; IR (cm-1) 3273, 3207, 3126, 3080, 
2921, 2850, 1616, 1585, 1547, 1489, 1444, 1382, 1350, 
1283, 1218, 1178, 1119, 976; 1H NMR (300 MHz, DMSO-
d6) δ 1.0-1.85 (13H, m, cyclohexyland CH2CH2CH2), 2.55 
(2H, t, J = 7.6 Hz, CH2Ph), 3.06 (2H, m, CH2NHCO), 3.36 
(2H, s, ArCH2CONH), 4.32 (2H, d, J = 6.2 Hz, OCH2), 
6.81 (1H, d, J = 7.5 Hz, ArH), 7.13-7.29 (6H, m, ArH and 
PhH), 7.67 (1H, s, ArH), 7.70 (1H, d, J = 8.3 Hz, ArH), 
7.95 (1H, s, H-8), 8.06 (1H, t br, J = 5.5 Hz, CONH), 
9.18 (1H, s, ArNHAr); 13C NMR (125 MHz, DMSO-d6) δ 
25.2, 26.0, 29.2, 30.9, 32.5, 36.8, 38.2, 68.3, 71.0, 116.6, 
121.4, 125.7, 128.1, 128.2, 128.2, 136.6, 141.7, 155.5, 
170.0; LCMS (ES+) m/z 499.54 [M+H]+; HRMS (ES+) 
calcd for C29H35N6O2 [M+H]
+ 499.2816, found 499.2820; 
λmax (EtOH) 272 nm.
Synthesis of 2-arylaminopurine derivatives (48-53)
2,2,2-Trifluoroethyl-3-(6-cyclohexylmethoxy-9H- 
purin-2-ylamino)phenylmethanesulfonate (26, 1 mol. 
equiv.),1,8-diazabicyclo[5.4.0]undec-7-ene (3 mol. 
equiv.), and the appropriate amine (2.5 mol. equiv.) were 
heated under microwave conditions in anhydrous THF (2 
mL) for 15 min at 160 °C. After removal of the solvent, 
the white solid was extracted with EtOAc or THF and 
washed with saturated aqueous NaHCO3 solution and 
brine. The filtrate was concentrated to give a residue that 
was purified by medium pressure chromatography or using 
the Biotage SP4 purification system.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-
phenyl]-N,N-dimethylmethanesulfonamide (48)
The product from the reaction of 2,2,2-trifluoroethyl-
3-(6-cyclohexylmethoxy-9H-purin-2-ylamino) phenyl-
methane sulfonate (26) (46 mg, 0.09 mmol), 
1,8-diazabicyclo[5.4.0]undec-7-ene (42 μl, 0.18 mmol), 
and dimethylamine (12 μL, 0.18 mmol), was purified by 
chromatography (silica; EtOAc-petrol; 8:2) to give the 
title compound as an off-white solid (16 mg, 40%): Rf 
= 0.14 (EtOAc); mp 132-133 °C; IR (cm-1) 2922, 2849, 
2158, 2027, 1968, 1588, 1440, 1309, 1118; 1H NMR (300 
MHz, DMSO-d6) δ 1.0–1.8 (11H, m, cyclohexyl), 2.75 
(6H, s, N(CH3)2), 4.34 (2H, s, SO2CH2), 4.36 (2H, d, J = 
6.2 Hz, OCH2), 6.96 (1H, d, J = 7.6 Hz, ArH), 7.27 (1H, 
dd, J = 7.8, 7.9 Hz, ArH), 7.82 (1H, d, J = 7.6 Hz, ArH), 
7.86 (1H, s, ArH), 8.02 (1H, s, H8), 9.40 (1H, s, ArNHAr), 
12.78 (1H, br, N9-H); 13C NMR (75 MHz, DMSO-d6) δ 
25.57, 26.37, 29.62, 37.74, 39.36, 49.55, 54.77, 71.52, 
118.68, 121.09, 123.60, 128.62, 130.05, 140.26, 141.74, 
155.77; LCMS (ES+) m/z 445 [M+H]+; Found: C, 56.79; 
H, 6.31; N, 18.61. C21H28N6O3S requires C, 56.74; H, 6.35; 
N, 18.91%; λmax (EtOH) 212.5, 272.5, 294 nm.
1-(3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenylmethanesulfonyl)piperidine (49)
The product from the reaction of 2,2,2-trifluoroethyl-
3-(6-cyclohexylmethoxy-9H-purin-2-ylamino) phenyl-
methanesulfonate (26) (75 mg, 0.15 mmol),1,8-
diazabicyclo[5.4.0]undec-7-ene (68 μL, 0.45 mmol), 
and piperidine (37 μL, 0.38 mmol) was purified by 
chromatography (silica; EtOAc-MeOH; 9.5:0.5) to give 
the title compound as a white solid (54 mg, 75%): Rf = 
0.26 (EtOAc); mp 217-218 °C; IR (cm-1) 2922, 2853, 
2362, 2338, 1589, 1541, 1437, 1396, 1350, 1310, 1242, 
1152, 1121, 1067, 1045; 1H NMR (300 MHz, DMSO-d6) δ 
1.0–1.8 (11H, m, cyclohexyl), 1.47 (6H, m, piperidyl CH), 
3.12 (4H, br m, 2 × piperidyl CH2), 4.28 (2H, s, ArCH2), 
4.35 (2H, d, J = 6.2 Hz, OCH2), 6.94 (1H, d, J = 7.5 Hz, 
ArH), 7.25 (1H, dd, J = 7.9, 8.0 Hz, ArH), 7.81 (1H, d, J 
= 8.5 Hz, ArH), 7.88 (1H, s, ArH), 8.02 (1H, s, H-8), 9.42 
(1H, s, ArNHAr), 12.76 (1H, br, N9-H); LCMS (ES+) m/z 
485.18 [M+H]+; Anal. calcd for C24H32N6O3S: C, 59.48; H, 
6.66; N, 17.34%; found: C, 59.22; H, 6.56; N, 17.16; λmax 
(EtOH) 272, 293 nm.
1-(3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenylmethanesulfonyl)piperazine (50)
The product from the reaction of 2,2,2-trifluoroethyl-
3-(6-cyclohexylmethoxy-9H-purin-2-ylamino)
phenylmethanesulfonate (26) (75 mg, 0.15 mmol), 
1,8-diazabicyclo[5.4.0]undec-7-ene (68 μL, 0.45 mmol), 
and piperazine (45 mg, 0.53 mmol) was purified using 
Biotage SP4 (12 + M KP-NH silica cartridge; EtOAc-
MeOH; 9.5:0.5) to give the title compound as a colourless 
solid (66 mg, 91%): Rf = 0.73 (NH2-modified silica; EtOAc-
MeOH; 8:2); mp 127-128 °C; IR (cm-1) 2922, 2853, 2362, 
2338, 1589, 1541, 1437, 1396, 1350, 1310, 1242, 1152, 
1121, 1067, 1045; 1H NMR (300 MHz, DMSO-d6) δ 1.0–1.9 
(11H, m, cyclohexyl), 3.11 (4H, br, 2 × piperazinyl CH2), 
3.16 (4H, br, 2 × piperazinyl CH2), 4.33 (2H, s, ArCH2), 
4.35 (2H, d, J = 6.7 Hz, OCH2), 6.95 (1H, d, J = 7.5 Hz, 
ArH), 7.26 (1H, dd, J = 7.8, 7.9 Hz, ArH), 7.62 (1H, d, J 
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= 8.0 Hz, ArH), 7.91 (1H, s, ArH), 7.97 (1H, s, H-8), 9.34 
(1H, s, ArNHAr), 12.77 (1H, br, N9-H); LCMS (ES+) m/z 
486 [M+H]+; HRMS (ES+) calcd for C23H32N7O3S [M+H]
+ 
484.2136, found 484.2145; λmax (EtOH) 272, 293 nm.
1-[3-(6-Cyclohexylmethoxy-9H-purin-2-
ylamino)phenyl]-N-(3-dimethylaminopropyl)
methanesulfonamide (51)
The product from the reaction of 2,2,2-trifluoroethyl-
3-(6-cyclohexylmethoxy-9H-purin-2-ylamino)
phenylmethanesulfonate (26) (60 mg, 0.12 mmol),1,8-
diazabicyclo[5.4.0]undec-7-ene (55 μL, 0.36 mmol), 
and N,N-dimethylpropane-1,3-diamine (38 μL, 0.30 
mmol) was purified using the Biotage SP4 (12 + M KP-
NH silica cartridge; EtOAc-MeOH; 8.5:1.5) to give the 
title compound as a white solid (55 mg, 92%): Rf = 0.13 
(NH2-modified silica; EtOAc-MeOH; 9:1); mp 167-
168 °C; IR (cm-1) 2924, 2850, 1589, 1541, 1489, 1441, 
1390, 1356, 1308, 1243, 1214, 1146, 1121; 1H NMR (300 
MHz, DMSO-d6) δ 1.00-1.90 (13H, m, cyclohexyl and 
NCH2CH2CH2NH), 2.07 (6H, s, 2 × CH3), 2.19 (2H, t, J = 
6.9 Hz, Me2NCH2), 2.95 (2H, t, J = 6.7 Hz, CH2CH2NH), 
4.23 (2H, s, ArCH2), 4.35 (2H, d, J = 5.8 Hz, OCH2), 6.92 
(1H, d, J = 5.8 Hz, ArH), 7.26 (1H, dd, J = 7.8, 7.8 Hz, 
ArH), 7.83 (1H, d, J = 7.7 Hz, ArH), 7.84 (1H, s, ArH), 
8.00 (1H, s, H-8), 9.35 (1H, s, ArNHAr); LCMS (ES+) 
m/z 502.36 [M+H]+; HRMS (ES+) calcd for C24H36N7O3S 
[M+H]+ 502.2595, found 502.2600; Anal. calcd for 
C24H35N7O3S: C, 57.46; H, 7.03; N, 19.55%; found: C, 
57.76; H, 7.15; N, 19.67%; λmax (EtOH) 272, 293 nm.
1-[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(4-methoxybenzyl)methanesulfonamide (52)
The product from the reaction of2,2,2-trifluoroethyl-
3-(6-cyclohexylmethoxy-9H-purin-2-ylamino)
phenylmethanesulfonate (26) (150 mg, 0.3 mmol),1,8-
diazabicyclo[5.4.0]undec-7-ene (136 μL, 0.9 mmol), and 
4-methoxybenzylamine (97 μL, 0.75 mmol) was purified 
by chromatography (silica; EtOAc-petrol; 9:1) to give the 
title compound as a white solid (143 mg, 89%): Rf = 0.37 
(EtOAc); mp 118-119 °C; IR (cm-1) 2922, 2850, 2361, 
2338, 2026, 1589, 1541, 1506, 1444, 1395, 1354, 1303, 
1244, 1121, 1030; 1H NMR (300 MHz, DMSO-d6) δ 1.00-
1.90 (11H, m, cyclohexyl), 3.70 (3H, s, OCH3), 4.05 (2H, 
d, J = 9.0 Hz, ArCH2NH), 4.22 (2H, s, ArCH2SO2NH), 
4.35 (2H, d, J = 6.1 Hz, OCH2), 6.86–6.90 (3H, m, 3 × 
ArH), 7.23 (2H, d, J = 7.0 Hz, ArH), 7.26 (1H, dd, J = 
7.6, 7.9 Hz, ArH), 7.57 (1H, t, J = 6.0 Hz, SO2NH), 7.81-
7.85 (2H, m, 2 × ArH), 7.99 (1H, s, H-8), 9.37 (1H, s, 
ArNHAr), 12.77 (1H, s br, N9-H); LCMS (ES+) m/z 
537.40 [M+H]+; HRMS (ES-) calcd for C27H31N6O4S [M-
H]- 535.2133, found 535.2143; λmax (EtOH) 272 nm.
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)phenyl]
methanesulfonamide (53)
[3-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)
phenyl]-N-(4-methoxybenzyl)methanesulfonamide (52) 
(80 mg, 0.15 mmol) was stirred in neat TFA (2 mL) for 6 
h. Upon completion of the reaction, the TFA was removed 
in vacuo and the residual solid was extracted into EtOAc 
(50 mL). The organic layer was washed with aqueous 
NaHCO3 (50 mL), dried (Na2SO4) and concentrated to 
give a white solid. Purification by chromatography (silica; 
EtOAc) afforded the title compound as a white powder (53 
mg, 85%): Rf = 0.50 (EtOAc); mp 134-135 °C; IR (cm
-1) 
3344, 2924, 2852, 2361, 2338, 1719, 1599, 1542, 1488, 
1449, 1393, 1336, 1256, 1156, 1123, 1046; 1H NMR (300 
MHz, DMSO-d6) δ 1.0–1.9 (11H, m, cyclohexyl), 4.20 
(2H, s, ArCH2SO2NH2), 4.34 (2H, d, J = 6.0 Hz, OCH2), 
6.85 (2H, s br, SO2NH2), 6.93 (1H, d, J = 7.3 Hz, ArH), 
7.26 (1H, dd, J = 7.8, 7.9 Hz, ArH), 7.75 (1H, s, ArH), 
7.85 (1H, d, J = 8.3 Hz, ArH), 7.97 (1H, s, H-8), 9.37 
(1H, s, ArNH), 12.77 (1H, br, N9-H); LCMS (ES+) m/z 
417 [M+H]+; HRMS (ES-) calcd for C19H23N6O3S [M-H]
- 
417.1703, found 417.1702; λmax (EtOH) 272, 292 nm.
Synthesis of 2-amino-6-alkoxypurines (55 and 56)
Sodium (5 mol. equiv.) was cautiously dissolved 
in the appropriate alcohol (3.4 mL/mmol), and to the 
resulting solution was added 2-amino-6-chloropurine (54, 
1 mol. equiv). The mixture was stirred at reflux for 18 h 
and cooled to room temperature. The alcohol was removed 
in vacuo and water (100 mL) was added to the residual 
solid. The resulting solution was neutralised with AcOH. 
Purification was achieved either by cooling the mixture 
to ~ 3 °C and collecting the product by filtration under 
vacuum, or by extracting the product into EtOAc (3 × 100 
mL). The combined extracts were dried (Na2SO4) and the 
solvent was removed to give the 6-alkoxy-2-aminopurine 
that was used directly in subsequent steps.
O6-Ethylguanine (55)
The title compound was prepared using 2-amino-
6-chloropurine (3.0 g, 18 mmol) and sodium (1.2 g, 53 
mmol) in EtOH (80 mL) to give a colourless solid (2.9 g, 
93%): mp 280-281 °C (dec); 1H NMR (300 MHz, DMSO-
d6) δ 1.35 (3H, t, J = 7.0 Hz, CH2CH3), 4.43 (2H, q, J = 
7.0 Hz, OCH2), 6.20 (2H, s, NH2), 7.81 (1H, s, H-8), 12.41 
(1H, br, N9-H).
(±)-O6-sec-Butylguanine (56)
The title compound was prepared using 2-amino-6-
chloropurine (1.5 g, 8.9 mmol), sodium (0.60 g, 27 mmol), 
butan-2-ol (25 mL) and THF (15 mL) to give a colourless 
powder (1.46 g, 80%): mp 84-85 °C; 1H NMR (300 MHz, 
DMSO-d6) δ 0.91 (3H, t, J = 7.4 Hz, CH3CH2), 1.30 (3H, 
d, J = 6.3 Hz, CHCH3), 1.62 (2H, m, CH2CH3), 5.32 (1H, 
m, OCH), 6.20 (2H, s, 2-NH2), 7.79 (1H, s, H-8), 12.29 
(1H, br, N9-H).
Synthesis of 6-alkoxy-2-fluoropurines (57 and 58)
To a stirred solution of aqueous HBF4 (48%, 20 
mol. equiv.) at 0 °C was added the appropriate 2-amino-
6-alkoxypurine (1 mol. equiv.). To the resulting solution 
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was added NaNO2 (2 mol. equiv.) in water (1 mL/mmol of 
NaNO2) dropwise, ensuring that the reaction temperature 
did not exceed 10 °C. The reaction mixture was allowed to 
warm to room temperature and was stirred for 24 h before 
being neutralised slowly with saturated Na2CO3 solution. 
The resulting precipitate was collected via filtration and 
washed with water. The solid was stirred for 1 h in EtOAc 
(4 × 150 mL) and filtered. The combined filtrates were 
concentrated under reduced pressure to yield the product, 
which was used directly.
6-Ethoxy-2-fluoropurine (57)
The title compound was synthesised using O6-
ethylguanine (55) (2.5 g, 14 mmol), 48% aqueous HBF4 
(25 mL, 280 mmol) and NaNO2 (1.9 g, 28 mmol) to give a 
colourless solid (1.26 g, 50%): mp 220-222 °C; 1H NMR 
(300 MHz, DMSO-d6) δ 1.41 (3H, t, J = 7.0 Hz, CH2CH3), 
4.57 (2H, q, J = 7.0 Hz, OCH2), 8.39 (1H, s, H-8), 13.40 
(1H, br, N9-H).
(±)-6-sec-Butoxy-2-fluoropurine (58)
The title compound was synthesised using O6-sec-
butylguanine (56) (1.0 g, 4.8 mmol), 48% aqueous HBF4 
(10 mL, 45 mmol) and NaNO2 (0.67 g, 9.7 mmol) to give 
a colourless solid (369 mg, 36%): mp 189-190 °C (dec); 
1H NMR (300 MHz, DMSO-d6) δ 0.92 (3H, t, J = 7.4 Hz, 
CH3CH2), 1.35 (3H, d, J = 6.3 Hz, CHCH3), 1.71 (2H, m, 
CH2CH3), 5.32 (1H, m, OCH), 8.38 (1H, s, H-8), 13.34 
(1H, br, N9-H); 19F NMR (470 MHz, DMSO-d6) δ -51.94 
(s, ArF).
N-(3-Dimethylaminopropyl)-2-[3-(6-ethoxy-9H-purin-
2-ylamino)phenyl]acetamide (59)
The title compound was synthesised according 
to Method I using 6-ethoxy-2-fluoropurine (57) 
(100 mg, 0.55 mmol), 2-(3-aminophenyl)-N-(3-
dimethylaminopropyl)acetamide (see ESI S49; 291 mg, 
1.2 mmol), TFE (4 mL), and TFA (0.20 mL, 2.8 mmol). 
The crude product was purified using the Biotage SP4 
purification system (25 + M KP-NH Si cartridge; MeOH-
EtOAc; 1:9 to 3:7) to give a semi-pure compound that 
was further purified by semi-prep HPLC (5 → 100% v/v 
acetonitrile: water: NH4OH over 25 min; flow-rate 12.75 
mL/min, wavelength 280 nm) to give the title compound 
as a brown gum (43 mg, 20%):Rf = 0.06 (NH2–modified 
silica; MeOH-EtOAcl 1:9); mp 178-179 °C; IR (cm-1) 
3290, 2937, 2762, 1641, 1602, 1571, 1534, 1493, 1433, 
1381, 1336, 1317, 1251, 1163, 1122, 1019;1H NMR (300 
MHz, DMSO-d6) δ 1.42 (3H, t, J = 7.1 Hz, CH3CH2O), 
1.52 (2H, qn, J = 6.9 Hz, NCH2CH2CH2NH), 2.07 (6H, s, 
2 × CH3), 2.18 (2H, t, J = 7.1 Hz, Me2NCH2), 3.06 (2H, 
m, CH2CH2NHCO), 3.34 (ArCH2, overlap with H2O), 
4.57 (2H, q, J = 7.0 Hz, OCH2), 6.81 (1H, d, J = 7.6 Hz, 
ArH), 7.18 (1H, dd, J = 7.7, 7.8 Hz, ArH), 7.65 (2H, m, 
2 × ArH), 8.00 (2H, br, CONH and H-8), 9.28 (1H, s, 
ArNHAr), 12.81 (1H, br, N9-H); LCMS (ES+) m/z 398.54 
[M+H]+;λmax (EtOH) 272 nm.
(±)-2-[3-(6-sec-Butoxy-9H-purin-2-ylamino)phenyl]-N-
(3-dimethylaminopropyl)acetamide (60)
The title compound was synthesised according 
to Method I using 6-sec-butoxy-2-fluoropurine 
(58) (75 mg, 0.36 mmol), 2-(3-aminophenyl)-N-(3-
dimethylaminopropyl)acetamide (see ESI S49; 190 
mg, 0.81 mmol), TFE (3 mL), and TFA (0.13 mL, 1.8 
mmol). The crude product was purified using the Biotage 
SP4 purification system (25 + M KP-NH Si cartridge; 
EtOAc → MeOH-EtOAc; 1.5:8.5) to give a semi-pure 
compound that was further purified by semi-prep HPLC 
(5 → 100% v/v acetonitrile: water: NH4OH over 25 min; 
flow-rate 12.75 mL/min, wavelength 280 nm) to give 
the title compound as a white solid (43 mg, 28%): Rf = 
0.08 (NH2-modified silica; MeOH-EtOAc; 1:9); mp 97-
98 °C; IR (cm-1) 3283, 2970, 2935, 2777, 2164, 1587, 
1538, 1493, 1438, 1373, 1313, 1245, 1215, 1165, 1114; 
1H NMR (300 MHz, DMSO-d6) δ 0.95 (3H, t, J = 7.4 Hz, 
CH3CH2CH(CH3)O), 1.37 (3H, d, J = 6.2 Hz, OCH(CH3)), 
1.51 (2H, qn, J = 7.0 Hz, NCH2CH2CH2N), 1.65-1.84 (2H, 
m, CH3CH2CH), 2.05 (6H, s, 2 × NCH3), 2.16 (2H, t, J = 
7.1 Hz, Me2NCH2), 3.06 (2H, m, CH2CH2NHCO), 3.34 
(ArCH2, overlap with H2O), 5.42 (1H, m, OCH), 6.80 (1H, 
d, J = 7.5 Hz, ArH), 7.18 (1H, dd, J = 7.8, 7.8 Hz, ArH), 
7.62 (1H, s, ArH), 7.67 (1H, d, J = 7.7 Hz, ArH), 7.98 
(1H, s, H-8), 9.24 (1H, s, ArNHAr), 12.78 (1H, br, N9-
H);LCMS (ES+) m/z 426.46 [M+H]+; HRMS (ES+) calcd 
for C22H32N7O2 [M+H]
+ 426.2612, found 426.2613; λmax 
(EtOH) 272 nm.
[3-(6-Ethoxy-9H-purin-2-ylamino)phenyl]acetic acid 
(61)
6-Ethoxy-2-fluoropurine (57) (0.90 g, 5.0 mmol), 
3-aminophenylacetic acid (1.87 g, 12.4 mmol) were 
combined in TFE (7 mL), to which TFA (1.8 mL, 25 
mmol) was added and the reaction mixture was heated to 
reflux for 24 h. After concentration in vacuo, THF (20 mL) 
and NaOH aqueous solution (1 M, 15 mL) were added to 
the residue and the resulting mixture was stirred overnight. 
The pH was adjusted to 1 with conc. HCl and the product 
was extracted with EtOAc (250 mL). The organic phase 
was separated, washed with 10 % HCl solution and dried 
(NaSO4). Removal of the solvent gave crude product, 
to which Et2O (100 mL) was added. After allowing the 
mixture to stand for 3 h the resulting precipitate was 
collected by filtration under vacuum and washed with 
Et2O (30 mL). Recrystallisation from MeOH gave the 
pure product as a light brown powder (729 mg, 47%): mp 
205-206 °C; 1H NMR (300 MHz, DMSO-d6) δ 1.42 (3H, 
t, J = 7.0 Hz, CH3CH2O), 3.50 (2H, s, ArCH2,), 4.57 (2H, 
q, J = 6.9 Hz, OCH2), 6.81 (1H, d, J = 7.2 Hz, ArH), 7.20 
(1H, dd, J = 7.7, 7.8 Hz, ArH), 7.65 (1H, d, J = 8.1 Hz, 
ArH), 7.75 (1H, s, ArH), 7.90 (1H, s, H-8), 9.29 (1H, s, 
ArNHAr), 12.78 (1H, br, N9-H); LCMS (ES+) m/z 314.21 
[M+H]+.
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2-[3-(6-Ethoxy-9H-purin-2-ylamino)-phenyl]-N-(3-
imidazol-1-ylpropyl)acetamide (62)
Carboxylic acid 61 (80 mg, 0.26 mmol) was treated 
with carbonyldiimidazole (84 mg, 0.52 mmol) and DIPEA 
(93 μL, 0.52 mmol) in DMF (3 mL) and stirred for 1.5 
h at room temperature. N-(3-aminopropyl)imidazole (130 
mg, 0.80 mmol) was added in one portion and stirring 
was continued overnight. Solvents were removed and the 
residue was extracted into EtOAc. The extract was washed 
with saturated aqueous NaHCO3 and dried (Na2SO4). The 
solvent was removed to afford the crude product, which 
was purified using a Biotage SP4 purification system (12 
+ M KP-NH silica cartridge; EtOAc → 15% MeOH/ 
EtOAc), followed by purification by semi-prep HPLC (5 
→ 100% v/v acetonitrile: water: NH4OH over 25 min; flow-
rate 12.75 mL/min, wavelength 280 nm) to give an off-
white solid (57 mg, 52%): Rf = 0.55 (NH2-modified silica; 
MeOH-EtOAc; 3:7); mp 176-177 °C; IR (cm-1) 3268, 
2953, 2926, 2362, 2337, 1636, 1578, 1539, 1493, 1436, 
1379, 1315, 1251, 1165, 1110, 1079; 1H NMR (300 MHz, 
DMSO-d6) δ 1.42 (3H, t, J = 7.0 Hz, CH3CH2O), 1.83 
(2H, m, CH2CH2CH2NH), 3.01 (2H, m, CH2CH2NHCO), 
3.38 (ArCH2, overlap with H2O), 3.94 (2H, t, J = 6.8 Hz, 
ImCH2), 4.57 (2H, q, J = 7.1 Hz, OCH2), 6.83 (1H, d, J 
= 7.6 Hz, ArH), 6.86 (1H, s, imidazole-H), 7.13 (1H, s, 
imidazole-H), 7.19 (1H, dd. J = 7.7, 7.7 Hz, ArH), 7.58 
(1H, s, imidazole-H), 7.65-7.71 (2H, m, 2 × ArH), 8.00 
(1H, s, H-8), 8.07 (1H, t, J = 5.1 Hz, CONH), 9.27 (1H, s, 
ArNHAr); LCMS (ES+) m/z 421.34 [M+H]+; HRMS (ES+) 
calcd for C21H25N8O2 [M+H]
+ 421.2095, found 421.2099; 
λmax (EtOH) 272, 292 nm.
6-Chloro-2-fluoro-9H-purine (63) [36]
To a stirred solution of HBF4 (48% aqueous, 120 
mL) at 0 ºC, was added 2-amino-6-chloropurine (6.0 
g, 35.0 mmol). Over 20 min, a solution of NaNO2 (4.9 
g, 70.0 mmol) in water (200 mL) was added dropwise, 
ensuring the temperature remained close to 0 ºC. The pale 
yellow solution was raised to room temperature and stirred 
for 18 h. The resulting solution was neutralised to pH 7 
in an ice bath at 0 °C, by addition of Na2CO3 (6.00 g) 
in water (200 mL). Solvents were removed in vacuo and 
the residual solid was redissolved in MeOH (100 mL) and 
adsorbed onto silica (250 mL). The crude material was 
purified by chromatography (silica; MeOH-DCM; 1:9) to 
afford the title compound as a white crystalline solid (4.52 
g, 75%): mp 158-159 °C (Lit.,32 mp 161-162 °C); IR (cm-1) 
2964, 2785, 1735, 1581;1H NMR (300 MHz, DMSO-d6) 
δ 8.72 (1H, s, H-8), 14.12 (1H, br s, N9-H); LCMS (ES+) 
m/z 172.6 [M+H]+; λmax (EtOH) 393 nm.
2-Fluoro-9H-purine (64) [37, 38]
To a stirred suspension of 6-chloro-2-fluoropurine 
(63) (0.30 g, 1.74 mmol) and palladium hydroxide on 
carbon (0.30 g) in MeOH (15 mL) was added ammonium 
formate (0.34 g, 5.35 mmol). The suspension was heated 
under reflux for 1h before filtering through a pad of Celite, 
eluting with MeOH (20 mL). Removal of volatiles under 
reduced pressure yielded the desired compound as a 
white solid (240 mg, 100%): mp 219 °C (dec.) (lit. [37], 
decomposed at 216 °C); 1H NMR (300 MHz, DMSO-d6) 
δ 8.60 (1H, s, H-8), 9.01 (1H, s, H-6), 13.9 (1H, s, NH-9); 
LCMS (ES+) m/z 139.2 [M+H]+.
1-(4-((9H-purin-2-yl)amino)phenyl)-3-(2-(piperidin-1-
yl)ethyl)urea (65)
Synthesis of the title compound was achieved 
according to Method I using 2-fluoro-9H-purine (64) (79 
mg, 0.57 mmol) and 1-(4-aminophenyl)-3-(2-(piperidin-
1-yl)ethyl)urea (see ESI; S20) (0.30 g, 1.15 mmol) with 
TFA (220 μL, 2.88 mmol) in TFE (4 mL). The product was 
isolated using the Biotage SP4 system (12 + M KP-NH; 
MeOH-EtOAc; 1:9) as a pale orange solid (95 mg, 45%): 
mp 96-98 °C; IR (cm-1) 3296, 3151, 2920, 2850, 1704, 
1629 υ(NN'C=O), 1581, 1547, 1512; 1H NMR (300 MHz, 
DMSO-d6) δ 1.45 (6H, m, CH2), 2.33 (6H, m, N(CH2)3), 
3.17 (2H, m, CH2), 6.02 (1H, m, NH), 7.28 (2H, d, J = 
8.5 Hz, H-2' and H-6'), 7.63 (2H, d, J = 8.5 Hz, H-3' and 
H-5'), 8.18 (1H, s, H-8), 8.52 (1H, s, H-6), 8.76 (1 H, s, 
NH-2), 9.28 (1H, s, NH-4´); 13C NMR (125 MHz, DMSO-
d6) δ 24.1, 25.5, 36.4, 54.0, 58.2, 118.1, 119.2, 134.3, 
134.9, 155.3, 156.8; LCMS (ES+) m/z 381.4 [M+H]+; 
HRMS (ES+) calcd for C19H24N8O [M+H]
+ 381.2146, 
found 381.2142; λmax (EtOH) 334.0, 280.0, 244.0 nm.
[3-(9H-Purin-2-ylamino)phenyl]acetic acid (66)
To a stirred mixture of 2-fluoro-9H-purine (64) (700 
mg, 5.1 mmol), 3-aminophenylacetic acid (1.72 g, 11.4 
mmol) in TFE (10 mL) was added TFA (1.9 mL, 25 mmol) 
and the reaction mixture was heated to reflux for 24 h. The 
reaction mixture was cooled to room temperature and then 
concentrated in vacuo to give a brown oil. The oil was 
redissolved in THF (10 mL) and a solution of KOH (2 g) 
in water (10 mL) was added, and the resulting solution 
was stirred overnight. THF was removed and the aqueous 
layer was adjusted to pH 6 with 2 M HCl. The resulting 
precipitate was collected by filtration under vacuum and 
washed with water (30 mL), Et2O (15 mL) and MeOH 
(15 mL). The resulting solid was dried to give the title 
compound as a light brown powder (462 mg, 34%): mp > 
250 °C; 1H NMR (DMSO-d6) δ 3.51 (2H, s, ArCH2), 6.82 
(1H, d, J = 7.5 Hz, ArH), 7.21 (1H, dd, J = 7.8, 7.9 Hz, 
ArH), 7.64 (1H, s, ArH), 7.79 (1H, d, J = 8.2 Hz, ArH), 
8.24 (1H, s, H-8), 8.81 (1H, s, H-6), 9.51 (1H, s, ArNH); 
LCMS (ES+) m/z 270.20 [M+H]+.
N-(3-Imidazol-1-yl-propyl)-2-[3-(9H-purin-2-ylamino)
phenyl]acetamide (67)
Carboxylic acid 66 (100 mg, 0.37 mmol) was stirred 
with carbonyldiimidazole (120 mg, 0.74 mmol) and DIPEA 
(133 μL, 0.74 mmol) in DMF (3 mL) at room temperature 
for 1.5 h. Following this, N-(3-aminopropyl)imidazole 
(185 mg, 1.48 mmol) was added in one portion and stirring 
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was continued overnight. Solvents were removed and the 
residue was extracted into EtOAc. The extract was washed 
with saturated aqueous NaHCO3 and dried (Na2SO4). The 
solvent was removed to afford the crude product, which 
was purified using a Biotage SP4 purification system (12 
+ M KP-NH silica cartridge; EtOAc → MeOH-EtOAc; 
1:4) to give a light brown solid (55 mg, 40%): Rf = 0.14 
(NH2-modified silica; MeOH-EtOAc; 1:4); mp 121-
122 °C; IR (cm-1) 3252, 2923, 2362, 2337, 1580, 1537, 
1394, 1333, 1282, 1214, 1180, 1105, 1080; 1H NMR (300 
MHz, DMSO-d6) δ 1.84 (2H, m, CH2CH2CH2), 3.02 (2H, 
m, CH2NH), 3.38 (2H, s, ArCH2CONH), 3.94 (2H, t, J 
= 6.8 Hz, CH2CH2CH2NHCO), 6.81-6.88 (2H, m, ArH 
and imidazole-H), 7.14 (1H, s, imidazole-H), 7.20 (1H, 
dd, J = 7.8, 7.9 Hz, ArH), 7.59 (2H, s and d, J = 7.4 Hz, 
imidazole-H and ArH), 7.78 (1H, d, J = 7.9 Hz, ArH), 8.10 
(1H, t br, J = 5.3 Hz, CONH), 8.23 (1H, s, H-8), 8.79 (1H, 
s, H-6), 9.46 (1H, s, ArNHAr); LCMS (ES+) m/z 375.39 
[M+H]+; HRMS (ES+) calcd for C19H21N8O [M+H]
+ 
375.1687, found 375.1689; λmax (EtOH) 272, 330 nm.
Synthesis of 2-arylamino-6-(dialkylaminovinyl)-
purines (69-73)
A solution of 6-ethynyl-2-phenylaminopurine (68) 
(50 mg, 0.21 mmol) and the required secondary amine 
(20.0 eq.) in anhydrous THF (2 mL) was subjected to 
microwave heating at 100 °C for 10 minutes in a sealed 
nitrogen flushed Biotage microwave vial. The cooled 
solution was partitioned between EtOAc (20 mL) and 
saturated NaHCO3 solution (20 mL). The organic extract 
was concentrated in vacuo to a yellow/orange syrup which 
was isolated using the Biotage SP4 purification system (12 
+ M KP-NH; MeOH-DCM; 0.5:9.5).
(E)-N-Phenyl-6-(2-(pyrrolidin-1-yl)vinyl)-9H-purin-2-
amine (69)
The title compound was prepared by reaction of 
pyrrolidine (355 μL, 4.23 mmol). Yellow solid (60 mg, 
93%): mp 138-140 °C; IR (cm-1) 3040, 2957, 1358, 
2921, 2852, 1630, 1559; 1H NMR (500 MHz, DMSO-
d6) δ 1.94 (4H, m, CH2), 3.36 (4H, m, CH2), 5.32-5.35 
(1H, d, J = 15.0 Hz, alkene CH), 6.85-6.87 (1H, t, J = 
10.1 Hz, H-4'), 7.22-7.26 (2H, dd, J = 9.9, 10.1 Hz, H-3' 
and H-5'), 8.82-8.84 (2H, d, J = 9.9 Hz, H-2' and H-6'), 
7.91 (1H, s, H-8), 8.54-8.57 (1H, d, J = 15.0 Hz, alkene 
CH), 8.97(1H, br s, NH), 12.52 (1H, br s, NH-9); LCMS 
(ES+) m/z 307.3 [M+H]+; HRMS (ES+) calcd for C17H18N6 
[M+H]+ 307.1671, found 307.1666; λmax (EtOH) 362.5, 
282.5, 254.5 nm.
(E)-6-(2-(Dimethylamino)vinyl)-N-phenyl-9H-purin-2-
amine (70)
The title compound was prepared by reaction 
dimethylamine solution 2.0 M in THF (2.13 mL, 
4.23 mmol). Yellow solid (63%): mp 129-131 °C; IR 
(cm-1) 2946, 2922, 2853, 1562, 1525; 1H NMR (500 
MHz, DMSO-d6) δ 2.99 (6H, s, NCH3), 5.15-5.18 (1H, 
d, J = 15.0 Hz, alkene CH), 6.63-6.65 (1H, t, J = 10.0 
Hz, H-4'), 7.00-7.04 (2H, dd, J = 9.9, 10.0 Hz, H-3' and 
H-5'), 7.60-7.62 (2H, d, J = 9.9 Hz, H-2' and H-6'), 7.70 
(1H, s, H-8), 8.08-8.11 (1H, d, J = 15.0 Hz, alkene CH), 
8.75(1H, br s, NH), 12.30 (1H, br s, NH-9); 13C NMR (125 
MHz, DMSO-d6) δ 84.5, 91.0, 117.9, 119.8, 122.0, 128.2, 
138.1, 141.9, 149.6, 151.5, 156.0, 156.6; LCMS (ES+) m/z 
281.2 [M+H]+; HRMS (ES+) calcd for C15H16N6 [M+H]
+ 
281.1508, found 281.1509; λmax (EtOH) 358.0, 281.0, 
253.0 nm.
(E)-6-(2-(Diethylamino)vinyl)-N-phenyl-9H-purin-2-
amine (71)
The title compound was prepared by reaction of 
diethylamine (442 μL, 4.23 mmol). Yellow solid (39 mg, 
60%): mp 127-129 °C; IR (cm-1) 2970, 2911, 1630, 1559; 
1H NMR (500 MHz, DMSO-d6) δ 1.11-1.13 (6H, t, J = 5.0 
Hz, CH3), 3.21-3.24 (4H, q, J = 5.0 Hz, NCH2), 5.52-5.53 
(1H, d, J = 15.0 Hz, alkene CH), 6.96-7.00 (1H, dd, J = 
10.1 Hz, H-4'), 7.19 (1H, s, H-8), 7.21-7.25 (2H, dd, J = 
9.8, 10.1 Hz, H-3' and H-5'), 7.40 (1H, br s, NH-2), 7.44-
7.46 (2H, d, J = 9.8 Hz, H-2' and H-6'), 8.18-8.21 (1H, 
d, J = 15.0 Hz, alkene CH), 13.05 (1H, br s, NH-9); 13C 
NMR (125 MHz, DMSO-d6) δ 29.7, 22.2, 121.3, 122.8, 
123.0, 129.3, 137.7, 140.16, 148.3, 151.1, 156.0, 158.3; 
LCMS (ES+) m/z 309.3 [M+H]+; HRMS (ES+) calcd for 
C17H20N6 [M+H]
+ 309.1824, found 309.1822; λmax (EtOH) 
359.0, 279.5, 253.5 nm.
(E)-6-(2-(Azepan-1-yl)vinyl)-N-phenyl-9H-purin-2-
amine (72)
The title compound was prepared by reaction of 
homopiperadine (480 μL, 4.23 mmol). Yellow solid (69 
mg, 98%): mp 135-137 °C; IR (cm-1) 3030, 2921, 2850, 
1629, 1559; 1H NMR (500 MHz, CDCl3) δ 1.49 (4H, m, 
CH2), 1.64-1.71 (4H, m, CH2), 3.28-3.38 (4H, m, CH2), 
5.49-5.52 (1H, d, J = 15.0 Hz, alkene CH), 6.95-6.99 (1H, 
t, J = 10.5 Hz, H-4'), 7.19 (1H, s, H-8), 7.22-7.26 (2H, 
dd, J = 9.5, 10.5 Hz, H-3' and H-5'), 7.32 (1H, br s, NH), 
7.44-7.46 (2H, d, J = 9.5 Hz, H-2' and H-6'), 8.23-8.26 
(1H, d, J = 15.0 Hz, alkene CH), 12.89 (1H, br s, NH-
9); 13C NMR (125 MHz, CDCl3) δ 25.9, 26.9, 28.2, 30.5, 
48.1, 56.0, 121.2, 122.8, 123.0, 129.3, 137.6, 140.1, 149.8, 
151.0, 156.0, 158.3; LCMS (ES+) m/z 335.3 [M+H]+; 
HRMS (ES+) calcd for C19H22N6 [M+H]
+ 335.1975, found 
335.1979;λmax (EtOH) 360.0, 238.0, 254.5 nm.
(R, E)-6-(2-(3-(Dimethylamino)pyrrolidin-1-yl)vinyl)-
N-phenyl-9H-purin-2-amine (73)
The title compound was prepared by reaction of 
(R)-3-dimethylaminopyrrolidine (540 μL, 4.23 mmol). 
Yellow solid (68 mg, 93%): mp 136-138 °C; IR (cm-1) 
2954, 2778, 2118, 1625, 1561, 1528; 1H NMR (500 MHz, 
CDCl3) δ 1.75-1.83 (1H, m, pyrrolidine H-3''), 2.08 (1H, 
m, pyrrolidine CH), 2.20 (6H, s, N(CH3)2), 2.70 (1H, m, 
pyrollidine CH), 3.49-3.50 (4H, m, CH2), 5.40 (1H, d, J = 
15.0 Hz, alkene CH), 6.79-7.00 (1H, t, J = 8.0 Hz, H-4'), 
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7.23-7.26 (2H, dd, J = 7.5, 8.0 Hz, H-3' and H-5'), 7.45-
7.46 (2H, d, J = 7.5 Hz, H-2' and H-6'), 8.31 (1H, d, J = 
15.0 Hz, alkene CH); 13C NMR (125 MHz, DMSO-d6) δ 
14.2, 29.7, 30.2, 44.3, 65.2, 76.8, 77.1, 77.3, 91.8, 121.2, 
122.7, 123.0, 129.3, 137.7, 140.0, 146.2, 151.2, 155.9, 
155.8; LCMS (ES+) m/z 350.3 [M+H]+; HRMS (ES+) 
calcd for C19H23N7 [M+H]
+ 350.2085, found 350.2088; 
λmax (EtOH) 263.0, 282.0, 361.0 nm.
Kinase inhibition conter-screening assays
Assays were conducted using ProfilerPro kinase 
selectivity assay kit 1 (Caliper Life Sciences). The ATP 
concentration used was that of the apparent ATP KM of 
each individual kinase and inhibitors were incubated at a 
single concentration of 2 μM, giving percentage inhibition 
values. Briefly, the protocol (provided with the kit on 
purchase) involved thawing of frozen enzyme and peptide/
ATP plates before reconstitution of the enzymes in buffer 
solution. Compound solutions were added to the enzyme 
plate, mixed and pre-incubated at 28 °C for 15 min before 
transferring the peptide/ATP solution to each well. The 
reaction mixture was incubated at 28 °C for a further 90 
min before addition of stop-buffer solution. The complete 
assay reactions were read using the Caliper EZ Reader II. 
For more information see: reference 16 and http://www.
perkinelmer.co.uk/product/ez-reader-ship-level-122919 
(accessed via internet on 05/07/2016).
Cellular growth inhibition assays
CellTiter-Blue Assay for Growth Inhibition. U2OS 
human osteosarcoma cells (American Type Culture 
Collection, Manassas, Virginia, United States) were grown 
in McCoy’s 5A medium supplemented with 1.5 mM 
L-glutamine, 25 mM HEPES, 2% penicillin/streptomycin 
(Invitrogen, Paisley, United Kingdom) and 10% (v/v) foetal 
calf serum (FCS) (Biosera, Ringmer, East Sussex, United 
Kingdom). MDA-MB-231 human breast cancer cells 
(American Type Culture Collection, Manassas, Virginia, 
United States) were grown in RPMI 1640 medium 
(Invitrogen) supplemented with 2 mM L-glutamine, 25 
mM HEPES, 2% penicillin/streptomycin and 10% (v/v) 
FCS. HeLa cells were grown in Dulbecco′s Modified 
Eagle Medium (D-MEM) (Invitrogen) supplemented with 
2% penicillin/streptomycin and 10% (v/v) FCS. All three 
cell lines were maintained in a humidified atmosphere of 
5% CO2 at 37°C. The medium was aspirated and the cells 
were washed with PBS (Invitrogen), trypsinized (Internal 
supply, 0.25% versene trypsin with EDTA), neutralized 
and counted. Cells were seeded into 384-well clear 
tissue culture treated microtiter plates (Corning B.V. Life 
Sciences, Amsterdam, The Netherlands) at 200 cells per 
well in a 45 μL volume of the respective media. Columns 
1 and 24 had no cells added and were plated with 45 μL of 
media alone. Cells were incubated at 37°C / 5% CO2. At 
24 hours after plating, compounds were three-fold serially 
diluted in large volume V-shape 384-well microplates 
(Greiner Bio-One, Stonehouse, Gloucestershire, United 
Kingdom) using an Evolution plate handling system 
(PerkinElmer Life Sciences, Waltham, Massachusetts, 
USA). Then 5 μL of diluted test compounds, etoposide 
as positive control (Sigma-Aldrich, Gillingham, Dorset, 
United Kingdom), or DMSO at 1% v/v final concentration 
(Fisher Scientific, Loughborough, Leicestershire, United 
Kingdom) were added to the wells using a MiniTrack V 
plate handling system (PerkinElmer Life Sciences). There 
were four replicates of each compound concentration, 
32 replicates of DMSO wells, and 32 replicates of wells 
containing no cells. Test compounds were screened at 
final concentrations of 100 μM, 33.33 μM, 11.11 μM, 
3.70 μM, 1.23 μM, 0.41 μM, 0.14 μM, and 0.05 μM. 
Etoposide was screened at final concentrations of 10 μM, 
3.33 μM, 1.11 μM, 0.37 μM, 0.12 μM, 0.041 μM, 0.014 
μM, and 0.005 μM. After 92 hours, 5 μL of CellTiter-Blue 
Reagent (Promega, Southampton, United Kingdom) was 
added to the cells using a Multidrop dispenser (Thermo 
Electron, Basingstoke, Hants, United Kingdom) and 
incubated for 4 hours in a humidified atmosphere of 5% 
CO2 at 37°C. After the incubation, the plates were placed 
at room temperature for 40 minutes before fluorescence 
was recorded (Ex = 560/ Em = 590) on an EnVision 2103 
plate reader (PerkinElmer Life Sciences). Data were 
plotted as percentage of DMSO control against compound 
concentration using GraphPad Prism 5 Software. The 50% 
growth inhibition (GI50) was calculated as the compound 
concentration required to reduce the cell number by 50% 
compared with the DMSO control.
Nek2 inhibition reversibility assay
The reversible nature of Nek2 inhibition by enamine 
70 was measured using a kinase inhibition-reversibility 
assay. The assay mixture initially contained the ‘peptide 
11’ substrate (5-FAM-KKLNRTLSVA-COOH; Caliper 
Life Sciences) and Nek2 protein (Invitrogen) at a 
concentration 100-fold that of the standard inhibitory 
activity assay. This solution in reaction buffer was pre-
incubated with inhibitor 70 at a concentration ten-fold its 
IC50, calculated to afford approximately 91% inhibition 
of Nek2. After incubation of the enzyme with compound 
70 for 30 min, the system was diluted 100- fold into a 
buffer solution containing both peptide-11 and ATP at 
the concentrations of the standard assay (details given 
in reference 12), affording a very low concentration of 
inhibitor (0.1 × IC50) with respect to other substrates. 
Following rapid 1:100 dilution, a reaction progress 
curve was generated by monitoring for levels of the 
phosphorylated substrate as described in reference 16 
using the Caliper EZ Reader II instrument at different 
times throughout the duration of the reaction.
Oncotarget34www.impactjournals.com/oncotarget
HPLC analysis of enamine stability
Solutions of 10 μM 72 were prepared in100% MEM 
media, 100% RPMI media, 10% (v/v) FCS in MEM, 10% 
BSA in water (v/v), 10 % FCS (v/v) in water, or 10 % (v/v) 
boiled FCS in water, DMSO and phosphate buffered water 
at pH 2, pH 7 and pH 10 by adding 10 μL of the 1 mM 
working stock of 72 in MeCN to 990 μL of each medium. 
A 50 μL aliquot was removed directly and immediately 
extracted as described below. At 5, 10, 15, 30, 60, 90, 
120, 180, 240, 360 and 1440 minutes after addition of the 
drug further aliquots of 50 μL were taken and extracted 
as below. At each time point the 50 μL of the test solution 
was added to 50 μL of acetonitrile (MeCN). Samples were 
mixed for 10 seconds on a vortex mixer and centrifuged 
at 15700 rcf for 5 minutes in a microcentrifuge. The 
supernatant solution from each sample was placed into an 
HPLC vial for analysis. Samples were analysed by reverse 
phase HPLC with PDA detection.
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